Updated on 2022/05/08

写真a

 
SATO, Yoshiaki
 
Organization
Nagoya University Hospital Maternity and Perinatal Care Center Lecturer
Graduate School
Graduate School of Medicine
Title
Lecturer

Degree 1

  1. Ph.D. ( 2008.1   Nagoya University ) 

Research Interests 1

  1. Perinatal brain injury, cell therapy, neuroprotection

Research Areas 2

  1. Others / Others  / Embryonic/Neonatal Medicine

  2. Life Science / Embryonic medicine and pediatrics

Research History 12

  1. Associate Professor, Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital

    2013.7

      More details

    Country:Japan

  2. Assistant Professor, Maternity & Perinatal Care Center, Nagoya University Hospital, Nagoya, Japan

    2010.10

      More details

    Country:Japan

  3. Assistant Professor, Maternity & Perinatal Care Center, Nagoya University Hospital, Nagoya, Japan

    2009.4 - 2010.9

      More details

    Country:Japan

  4. (Postdoctoral) Research fellow

    2007.4 - 2009.3

      More details

    Country:Japan

  5. 愛知県コロニー心身障害者コロニー中央病院 新生児科・非常勤医

    2006.1 - 2007.3

      More details

    Country:Japan

  6. 愛知県厚生連安城更生病院 小児科・医員

    2002.10 - 2004.3

      More details

    Country:Japan

  7. Fellowship in Pediatrics, Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    2002.4 - 2002.9

      More details

    Country:Japan

  8. Fellowship in Pediatrics, Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    2002.1 - 2002.3

      More details

    Country:Japan

  9. Fellowship in Neonatology, Facility of Perinatal Medicine, Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan

    2000.4 - 2001.12

      More details

    Country:Japan

  10. Fellowship in Pediatrics, Anjo Kosei Hospital, Anjo, Aichi, Japan

    1999.5 - 2000.3

      More details

    Country:Japan

  11. Residency in Pediatrics, Anjo Kosei Hospital, Anjo, Aichi, Japan

    1998.4 - 1999.4

      More details

    Country:Japan

  12. Residency in Internal Medicine, Surgery, Obstetrics and Gynecology, Anesthesiology, Primary Care, ER, Anjo Kosei Hospital, Anjo, Japan

    1997.5 - 1998.3

      More details

    Country:Japan

▼display all

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences   Pediatrics

    2003.4 - 2007.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1991.4 - 1997.3

      More details

    Country: Japan

Professional Memberships 11

  1. Japan Society of Perinatal and Neonatal of Medicine

    2010.4

  2. Japan Neuroscience Society

  3. Japan Society for Premature and Newborn Medicine

    2014.1

  4. 日本小児科学会

  5. The Japanese Society for Regenerative Medicine

  6. International Society for Stem Cell Research

  7. JAPAN PEDIATRIC SOCIETY

  8. JAPAN SOCIETY FOR NEONATAL HEALTH AND DEVELOPMENT

  9. THE JAPAN NEUROSCIENCE SOCIETY

  10. JAPAN SOCIETY OF PERINATAL AND NEONATAL MEDICINE

  11. THE JAPANESE SOCIETY FOR REGENERATIVE MEDICINE

▼display all

Awards 1

  1. 日本小児科学会学術研究賞

    2016.5   日本小児科学会  

    佐藤義朗

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

 

Papers 80

  1. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.

    Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y

    BMJ open   Vol. 12 ( 4 ) page: e057073   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/bmjopen-2021-057073

    PubMed

  2. Relationship between Neonatal MRI Findings and Emotional/Behavioral Evaluation in Early Childhood for Extremely Low-Birth-Weight Infants.

    Taniguchi A, Hayakawa M, Kataoka E, Fujishiro N, Sato Y

    Journal of clinical medicine   Vol. 11 ( 3 )   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/jcm11030772

    PubMed

  3. Hypertensive disorders of pregnancy and alterations in brain metabolites in preterm infants: A multi-voxel proton MR spectroscopy study.

    Katsuki S, Ushida T, Kidokoro H, Nakamura N, Iitani Y, Fuma K, Imai K, Nakano-Kobayashi T, Sato Y, Hayakawa M, Natsume J, Kajiyama H, Kotani T

    Early human development   Vol. 163   page: 105479   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.earlhumdev.2021.105479

    PubMed

  4. Trajectory of the incidence of brushes on preterm electroencephalogram and its association with neurodevelopment in extremely low birth weight infants.

    Maeda T, Kidokoro H, Tachibana T, Shiraki A, Yamamoto H, Nakata T, Fukasawa T, Kubota T, Sato Y, Kato T, Natsume J, Okumura A, Hayakawa M

    Brain & development   Vol. 43 ( 10 ) page: 979 - 987   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.braindev.2021.07.003

    PubMed

  5. A Study of Respiration Residual Template Matching Method for Neonatal Heartbeat Detection Using Doppler Sensor

    UEBAYASHI Shinji, MORI Tomoya, SATO Yoshiaki

      Vol. J104-B ( 3 ) page: 369 - 378   2021.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A neonatal heartbeat detection method using doppler sensor has been proposed. The method removes respiration waveform from the measured signal with template matching method synchronizing at each respiration period. The proportion of heartbeat to respiration rate of neonate decreases of 58% compared to adult, and desired effects of current frequrncy analyses will not be enough. The proposed method calculates heartbeat interval directly without frequency analyses, and measurements are stable even when the proportion is small. Through the experiments of the neonatal model which can simulate respiration and heartbet, and of an adult, we show that the measurement errors are 0.0-3.3%.

    DOI: 10.14923/transcomj.2020jbp3039

    CiNii Research

  6. Impact of maternal hypertensive disorders of pregnancy on brain volumes at term-equivalent age in preterm infants: A voxel-based morphometry study. International journal

    Takafumi Ushida, Hiroyuki Kidokoro, Noriyuki Nakamura, Satoru Katsuki, Kenji Imai, Tomoko Nakano-Kobayashi, Yoshinori Moriyama, Yoshiaki Sato, Masahiro Hayakawa, Jun Natsume, Hiroaki Kajiyama, Tomomi Kotani

    Pregnancy hypertension   Vol. 25   page: 143 - 149   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: Infants born to mothers with hypertensive disorders of pregnancy (HDP) reportedly have negative behavioral and neurodevelopmental outcomes. However, the effects of maternal HDP on infant brain growth have not been fully evaluated. We aimed to evaluate brain volumes and brain injury in preterm infants born to mothers with HDP using magnetic resonance (MR) imaging at term-equivalent age. STUDY DESIGN: In this cohort study, MR imaging was performed for 94 preterm infants born before 34 weeks of gestation at Nagoya University Hospital between 2010 and 2018. Twenty infants were born to mothers with HDP and 74 to mothers without HDP. MAIN OUTCOME MEASURES: Total brain volumes and regional volumetric alterations were assessed by voxel-based morphometry, and brain injury was evaluated using the Kidokoro global brain abnormality score. Developmental quotient was assessed at a corrected age of 1.5 years in 59 infants (HDP, n = 11; non-HDP, n = 48). RESULTS: No significant differences were observed in the gray and white matter volumes of the two groups (HDP: 175 ± 24 mL, 137 ± 13 mL, respectively; non-HDP: 172 ± 24 mL, 142 ± 13 mL, respectively). Additionally, no regional volumetric alterations were observed between the two groups after covariate adjustment (gestational age and infant sex). The total Kidokoro score and developmental quotient were similar in both groups. CONCLUSIONS: No significant differences in the global and regional brain volumes were observed. Further research is needed to confirm our findings at different time points of MR imaging and in different populations.

    DOI: 10.1016/j.preghy.2021.06.003

    PubMed

  7. Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy. Reviewed International journal

    Toshihiko Suzuki, Yoshiaki Sato, Yoshihiro Kushida, Masahiro Tsuji, Shohei Wakao, Kazuto Ueda, Kenji Imai, Yukako Iitani, Shinobu Shimizu, Hideki Hida, Takashi Temma, Shigeyoshi Saito, Hidehiro Iida, Masaaki Mizuno, Yoshiyuki Takahashi, Mari Dezawa, Cesar V Borlongan, Masahiro Hayakawa

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism   Vol. 41 ( 7 ) page: 1707 - 1720   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Perinatal hypoxic ischemic encephalopathy (HIE) results in serious neurological dysfunction and mortality. Clinical trials of multilineage-differentiating stress enduring cells (Muse cells) have commenced in stroke using intravenous delivery of donor-derived Muse cells. Here, we investigated the therapeutic effects of human Muse cells in an HIE model. Seven-day-old rats underwent ligation of the left carotid artery then were exposed to 8% oxygen for 60 min, and 72 hours later intravenously transplanted with 1 × 104 of human-Muse and -non-Muse cells, collected from bone marrow-mesenchymal stem cells as stage-specific embryonic antigen-3 (SSEA-3)+ and -, respectively, or saline (vehicle) without immunosuppression. Human-specific probe revealed Muse cells distributed mainly to the injured brain at 2 and 4 weeks, and expressed neuronal and glial markers until 6 months. In contrast, non-Muse cells lodged in the lung at 2 weeks, but undetectable by 4 weeks. Magnetic resonance spectroscopy and positron emission tomography demonstrated that Muse cells dampened excitotoxic brain glutamatergic metabolites and suppressed microglial activation. Muse cell-treated group exhibited significant improvements in motor and cognitive functions at 4 weeks and 5 months. Intravenously transplanted Muse cells afforded functional benefits in experimental HIE possibly via regulation of glutamate metabolism and reduction of microglial activation.

    DOI: 10.1177/0271678X20972656

    PubMed

  8. Diverse actions of cord blood cell therapy for hypoxic-ischemic encephalopathy. International journal

    Yoshiaki Sato, Masahiro Tsuji

    Pediatrics international : official journal of the Japan Pediatric Society   Vol. 63 ( 5 ) page: 497 - 503   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal death and permanent neurological deficits. However, effective treatments have not yet been established, except therapeutic hypothermia, which is not effective for severe HIE; therefore, developing a novel therapy for HIE is of the utmost importance. Stem cell therapy has recently been identified as a novel therapy for HIE. Among the various stem cell sources, ethical hurdles can be avoided by using stem cells that originate from non-embryonic or non-neural tissues, such as umbilical cord blood cells (UCBCs), which are readily available and can be exploited for autologous transplantations. Human UCBs are a rich source of stem and progenitor cells. Many recent studies have reported the treatment effect of UCBCs. Additionally, phase I clinical trials have already been conducted, showing this therapy's safety and feasibility. One advantage of stem cell therapies, including UCBC administration, is that they exert treatment effects through multifaceted mechanisms. According to the findings of several publications, replacement of lost cells, namely, engraftment and differentiation into neuronal cells, is not likely to be the main mechanism. However, the association between UCBCs and various mechanism of action, such as neurogenesis, angiogenesis, and anti-inflammation, has been suggested in many studies, and most mechanisms are due to growth factors secreted from UCBCs. These diverse actions of UCBC treatment are expected to exert a substantial effect on HIE, which has a complex injury mechanism.

    DOI: 10.1111/ped.14604

    PubMed

  9. Outcomes in symptomatic preterm infants with postnatal cytomegalovirus infection.

    Takemoto K, Oshiro M, Sato Y, Yamamoto H, Ito M, Hayashi S, Kato E, Kato Y, Hayakawa M

    Nagoya journal of medical science   Vol. 83 ( 2 ) page: 311 - 319   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Premature infants are at risk for developing symptomatic postnatal cytomegalovirus (CMV) disease, including sepsis-like syndrome. We performed a retrospective case-control study including infants born before 32 weeks of gestation and diagnosed with symptomatic postnatal CMV infection during the neonatal period. Neurodevelopmental outcome was evaluated using the Kyoto Scale of Psychological Development 2001 at 18 months of corrected age and at 3 years of age. Twenty-four infants were diagnosed with postnatal CMV infection; of them, 14 had sepsis-like symptoms and 10 had laboratory test abnormalities only. Home oxygen therapy was used significantly higher in the CMV-positive group compared with the control group at hospital discharge (52% vs 21%, P=0.032). The incidence of neurodevelopmental impairment was not significantly different between the two groups at 18 months of corrected age (29% vs 17%, P=0.48) and at 3 years of age (43% vs 29%, P=0.34). Postnatal CMV infection did not have a significant influence on neurodevelopmental outcomes of symptomatic preterm infants, although those in the CMV-positive group appeared worse. Larger studies with long-term follow-up are needed for a better understanding of continued neurodevelopmental outcomes in preterm infants with postnatal CMV infection.

    DOI: 10.18999/nagjms.83.2.311

    PubMed

  10. Brain damage caused by neonatal hypoxia-ischemia and the effects of hypothermia in severe combined immunodeficient (SCID) mice. International journal

    Yuko Ogawa, Emi Tanaka, Yoshiaki Sato, Masahiro Tsuji

    Experimental neurology   Vol. 337   page: 113577 - 113577   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of brain damage in newborns. Although therapeutic hypothermia has been shown to be neuroprotective against neonatal HIE in clinical trials, its effect is not satisfactory. Cell-based therapies have attracted much attention as novel treatments for HIE. Preclinical studies on a variety of human cell transplantation methods have been performed in immunodeficient/immunosuppressed animals, such as severe combined immunodeficient (SCID) mice, which lack functional T and B lymphocytes. The detailed characteristics of neonatal HIE in SCID mice, however, have not been delineated. In preclinical studies, novel therapies for neonatal HIE should be evaluated in combination with hypothermia, which has become a standard treatment for neonatal HIE. However, the effects of hypothermia in SCID mice have not been delineated. In the present study, we compared neonatal hypoxic-ischemic (HI) brain damage in SCID mice and wild-type mice treated with or without hypothermia. Male and female mouse pups were subjected to HI insult induced by unilateral common carotid artery ligation combined with systemic hypoxia on postnatal day 12. In the first 4 h after HI insult, body temperature was maintained at 36 °C for the normothermia groups or 32 °C for the hypothermia groups. The severity of brain damage in SCID mice did not differ from that in wild-type mice based on most evaluations, i.e., cerebral blood flow, hemiparesis, muscle strength, spontaneous activity, cerebral hemispheric volume, neuropathological injury, and serum cytokine levels, although spleen weight, brain weight, leukocyte counts and the levels of some cytokines in the peripheral blood were different between genotypes. The effects of hypothermia in SCID mice were comparable to those in wild-type mice based on most evaluations. Taken together, these findings indicate that SCID mice can be used as an appropriate preclinical model for cell therapies for neonatal HIE.

    DOI: 10.1016/j.expneurol.2020.113577

    Web of Science

    PubMed

  11. Non-invasive biosignals detection for continuous monitoring of a neonate using quartz crystal resonator Reviewed

    Shiro Watanabe, Yuichi Murozaki, Hirotaka Sugiura, Yoshiaki Sato, Kazuya Honbe, Fumihito Arai

    Sensors and Actuators A: Physical   Vol. 317   page: 112475 - 112475   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.sna.2020.112475

    Web of Science

  12. Metabolomic analysis and mass spectrometry imaging after neonatal stroke and cell therapies in mouse brains. International journal

    Tanaka E, Ogawa Y, Fujii R, Shimonaka T, Sato Y, Hamazaki T, Nagamura-Inoue T, Shintaku H, Tsuji M

    Scientific reports   Vol. 10 ( 1 ) page: 21881 - 21881   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Ischemic brain injury provokes complex, time-dependent downstream pathways that ultimately lead to cell death. We aimed to demonstrate the levels of a wide range of metabolites in brain lysates and their on-tissue distribution following neonatal stroke and cell therapies. Postnatal day 12 mice underwent middle cerebral artery occlusion (MCAO) and were administered 1 × 105 cells after 48 h. Metabolomic analysis of the injured hemisphere demonstrated that a variety of amino acids were significantly increased and that tricarboxylic acid cycle intermediates and some related amino acids, such as glutamate, were decreased. With the exception of the changes in citric acid, neither mesenchymal stem/stromal cells nor CD34+ cells ameliorated these changes. On-tissue visualization with matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) imaging revealed that the signal intensity of glutamate was significantly decreased in the infarct area, consistent with the metabolomic analysis, while its intensity was significantly increased in the peri-infarct area after MCAO. Although cell therapies did not ameliorate the changes in metabolites in the infarct area, mesenchymal stem cells ameliorated the increased levels of glutamate and carnitine in the peri-infarct area. MALDI-MS imaging showed the location-specific effect of cell therapies even in this subacute setting after MCAO. These methodologies may be useful for further investigation of possible treatments for ischemic brain injury.

    DOI: 10.1038/s41598-020-78930-x

    Web of Science

    PubMed

  13. Mesenchymal stem/stromal cells stably transduced with an inhibitor of CC chemokine ligand 2 ameliorate bronchopulmonary dysplasia and pulmonary hypertension. Reviewed International journal

    Toshihiko Suzuki, Yoshiaki Sato, Hidenori Yamamoto, Taichi Kato, Yuma Kitase, Kazuto Ueda, Haruka Mimatsu, Yuichiro Sugiyama, Atsuto Onoda, Shigeki Saito, Yoshiyuki Takahashi, Takayuki Nakayama, Masahiro Hayakawa

    Cytotherapy   Vol. 22 ( 4 ) page: 180 - 192   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Perinatal bronchopulmonary dysplasia (BPD) is defined as lung injury in preterm infants caused by various factors, resulting in serious respiratory dysfunction and high mortality. The administration of mesenchymal stem/stromal cells (MSCs) to treat/prevent BPD has proven to have certain therapeutic effects. However, MSCs can only weakly regulate macrophage function, which is strongly involved in the development of BPD. 7ND-MSCs are MSCs transfected with 7ND, a truncated version of CC chemokine ligand 2 (CCL2) that promotes macrophage activation, using a lentiviral vector. In the present study, we show in a BPD rat model that 7ND-MSC administration, but not MSCs alone, ameliorated the impaired alveolarization evaluated by volume density and surface area in the lung tissue, as well as pulmonary artery remodeling and pulmonary hypertension induced by BPD. In addition, 7ND-MSCs, but not MSCs alone, reduced M1 macrophages and the messenger RNA expressions of interleukin-6 and CCL2 in the lung tissue. Thus, the present study showed the treatment effect of 7ND-MSCs in a BPD rat model, which was more effective than that of MSCs alone.

    DOI: 10.1016/j.jcyt.2020.01.009

    Web of Science

    PubMed

  14. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Reviewed International journal

    Tsuji M, Sawada M, Watabe S, Sano H, Kanai M, Tanaka E, Ohnishi S, Sato Y, Sobajima H, Hamazaki T, Mori R, Oka A, Ichiba H, Hayakawa M, Kusuda S, Tamura M, Nabetani M, Shintaku H

    Scientific reports   Vol. 10 ( 1 ) page: 4603 - 4603   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Neonatal hypoxic-ischaemic encephalopathy (HIE) is a serious condition; many survivors develop neurological impairments, including cerebral palsy and intellectual disability. Preclinical studies show that the systemic administration of umbilical cord blood cells (UCBCs) is beneficial for neonatal HIE. We conducted a single-arm clinical study to examine the feasibility and safety of intravenous infusion of autologous UCBCs for newborns with HIE. When a neonate was born with severe asphyxia, the UCB was collected, volume-reduced, and divided into three doses. The processed UCB was infused at 12-24, 36-48, and 60-72 hours after the birth. The designed enrolment was six newborns. All six newborns received UCBC therapy strictly adhering to the study protocol together with therapeutic hypothermia. The physiological parameters and peripheral blood parameters did not change much between pre- and postinfusion. There were no serious adverse events that might be related to cell therapy. At 30 days of age, the six infants survived without circulatory or respiratory support. At 18 months of age, neurofunctional development was normal without any impairment in four infants and delayed with cerebral palsy in two infants. This pilot study shows that autologous UCBC therapy is feasible and safe.

    DOI: 10.1038/s41598-020-61311-9

    Web of Science

    PubMed

  15. A Novel Treatment with Stem Cells from Human Exfoliated Deciduous Teeth for Hypoxic-Ischemic Encephalopathy in Neonatal Rats. Reviewed International journal

    Yuma Kitase, Yoshiaki Sato, Kazuto Ueda, Toshihiko Suzuki, Alkisti Mikrogeorgiou, Yuichiro Sugiyama, Kohki Matsubara, Yuka Tsukagoshi Okabe, Shinobu Shimizu, Hitoshi Hirata, Hiroshi Yukawa, Yoshinobu Baba, Masahiro Tsuji, Yoshiyuki Takahashi, Akihito Yamamoto, Masahiro Hayakawa

    Stem cells and development   Vol. 29 ( 2 ) page: 63 - 74   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Recently, cell therapy has been developed as a novel treatment for perinatal hypoxic-ischemic encephalopathy (HIE), which is an important cause of neurological disorder and death, and stem cells from human exfoliated deciduous teeth (SHED) express early markers for mesenchymal and neuroectodermal stem cells. We investigated the treatment effect of SHED for HIE in neonatal rats. Seven-day-old rats underwent ligation of the left carotid artery and were exposed to 8% hypoxic treatment. SHED (1 × 105 cells) were injected via the right external jugular vein 24 h after the insult. The effect of intravenous administration of SHED cells was evaluated neurologically and pathophysiologically. In the evaluation of engraftment using quantum dots 655, only a few SHED were detected in the injured cortex. In the immunohistological evaluation 24 h after injection, the numbers of positive cells of active caspase-3 and anti-4 hydroxynonenal antiserum were lower in the SHED group than in the vehicle group. The number of Iba-1+ cells in the cortex was higher in the SHED group. However, the proportion of M1 microglia (Iba-1+/ED-1+) was significantly decreased, whereas M2 microglia (Iba-1+/CD206+) tended to increase in the SHED group. In the behavioral tests performed 5 months after hypoxic treatment, compared to the vehicle group, the SHED group showed significant elongation of the endurance time in the rotarod treadmill test, significantly ameliorated proportion of using the impaired hand in the cylinder test, significantly lower ratio of right/left front paw area in gait analysis, and significantly higher avoidance rate in the active avoidance test. In the in vitro experiment with cultured neurons exposed to oxygen-glucose deprivation, we confirmed the neuroprotective effect of the condition medium of SHED. These results suggested that intravenous administration of SHED exerted a treatment effect both histologically and functionally, possibly via a paracrine effect.

    DOI: 10.1089/scd.2019.0221

    Web of Science

    Scopus

    PubMed

  16. Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells. Reviewed International journal

    Kitase Y, Sato Y, Arai S, Onoda A, Ueda K, Go S, Mimatsu H, Jabary M, Suzuki T, Ito M, Saito A, Hirakawa A, Mukai T, Nagamura-Inoue T, Takahashi Y, Tsuji M, Hayakawa M

    Frontiers in cellular neuroscience   Vol. 14   page: 212 - 212   2020

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Fetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%-10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no established treatment. Therefore, the development of treatments is an urgent task. We aimed to develop a new FGR rat model with a gradual restrictive load of uterus/placental blood flow and to evaluate the treatment effect of the administration of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). To create the FGR rat model, we used ameroid constrictors that had titanium on the outer wall and were composed of C-shaped casein with a notch and center hole inside that gradually narrowed upon absorbing water. The ameroid constrictors were attached to bilateral ovarian/uterine arteries on the 17th day of pregnancy to induce chronic mild ischemia, which led to FGR with over 20% bodyweight reduction. After the intravenous administration of 1 × 105 UC-MSCs, we confirmed a significant improvement in the UC-MSC group in a negative geotaxis test at 1 week after birth and a rotarod treadmill test at 5 months old. In the immunobiological evaluation, the total number of neurons counted via the stereological counting method was significantly higher in the UC-MSC group than in the vehicle-treated group. These results indicate that the UC-MSCs exerted a treatment effect for neurological impairment in the FGR rats.

    DOI: 10.3389/fncel.2020.00212

    Web of Science

    PubMed

  17. Risk factors for absence of catch-up growth in small for gestational age very low-birthweight infants. Reviewed International journal

    Sakiko Arai, Yoshiaki Sato, Hideki Muramatsu, Hidenori Yamamoto, Fumiko Aoki, Yu Okai, Shinsuke Kataoka, Yu Hanada, Motoharu Hamada, Yoshihito Morimoto, Seiji Kojima, Jun Natsume, Yoshiyuki Takahashi

    Pediatrics international : official journal of the Japan Pediatric Society   Vol. 61 ( 9 ) page: 889 - 894   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Many small for gestational age (SGA) infants have catch-up growth during the first 2 years of life, but approximately 10% have no catch-up growth, and short stature continues into adulthood. Identification of risk factors for absence of catch-up growth at an early age may be useful for earlier diagnosis and earlier treatment. METHODS: This was a retrospective multicenter study. The subjects were SGA infants with very low-birthweight (VLBW), who were followed up until the age of 3 years. The risk factors for absence of catch-up growth were identified on statistical analysis. RESULTS: Of the 217 SGA infants in this study, 181 were in the catch-up group and 36 were in the no catch-up group. The catch-up rate was 83%. On multivariate analysis adjusted for gestational age, birthweight, birth height, and birth head circumference, multipara, Z and ΔZ scores of length at 12 months of corrected age, and the Z score of height at 24 months of corrected age were risk factors for lack of catch-up at 3 years. CONCLUSIONS: The length Z and ΔZ scores at 12 months of corrected age may be useful for an earlier diagnosis and earlier initiation of growth hormone treatment in VLBW infants.

    DOI: 10.1111/ped.13939

    Web of Science

    PubMed

  18. Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children

    Taniguchi Akinobu, Kawada Jun-ichi, Go Kiyotaka, Fujishiro Naozumi, Hosokawa Yosuke, Maki Yuki, Sugiyama Yuichiro, Suzuki Michio, Tsuji Takeshi, Hoshino Shin, Muramatsu Hideki, Kidokoro Hiroyuki, Kinoshita Fumie, Hirakawa Akihiro, Takahashi Yoshiyuki, Sato Yoshiaki, Natsume Jun, Nagoya Collaborative Clinical Research Team

    Japanese Journal of Infectious Diseases   Vol. 72 ( 4 ) page: 237 - 242   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee  

    <p>Human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are the leading causes of acute respiratory tract infection in children, and clinical manifestations of these virus infections are considered similar. To investigate the differences in clinical characteristics between HMPV and RSV infections in young children, we prospectively enrolled children < 3 years old who required hospitalization with acute respiratory tract infection due to HMPV or RSV at 10 hospitals in Japan. We enrolled 48 children with HMPV infection and 141 with RSV infection. Patients with HMPV infection were older than those with RSV infection. High-grade fever was more frequently observed in patients with HMPV infection, whereas no significant differences in respiratory symptoms were apparent. Abnormal serum lactate dehydrogenase values and consolidation shadows on chest X-ray were more frequently observed in patients with HMPV infection. During hospitalization, nasal mucus suction was more frequently required in patients with RSV infection. On the other hand, β2-adrenergic agonists, corticosteroids, and leukotriene receptor antagonists were more frequently used in patients with HMPV infection. These findings suggest that HMPV and RSV infections show similar respiratory symptoms, but HMPV infection is more likely to lead to the development of pneumonia, at least among hospitalized young children.</p>

    DOI: 10.7883/yoken.JJID.2018.480

    Web of Science

    PubMed

    CiNii Research

  19. Factors related to survival discharge in trisomy 18: A retrospective multicenter study. Reviewed International journal

    Eiko Kato, Yuma Kitase, Takashi Tachibana, Tetsuo Hattori, Akiko Saito, Yukako Muramatsu, Koji Takemoto, Hikaru Yamamoto, Seiji Hayashi, Ayako Yasuda, Yuichi Kato, Kuniko Ieda, Makoto Oshiro, Yoshiaki Sato, Masahiro Hayakawa

    American journal of medical genetics. Part A   Vol. 179 ( 7 ) page: 1253 - 1259   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Infants with trisomy 18 (T18) previously had a poor prognosis; however, the intensive care of these patients has markedly diversified the prognosis. We investigated the current situation of patients with T18, clarified factors for survival discharge, and surveyed actual home healthcare. A total of 117 patients with T18 admitted to nine institutions between 2000 and 2015 were retrospectively investigated. After excluding four patients whose outcomes were unclear, we divided 113 patients into two groups-the survival discharge group (n = 52) and the death discharge group (n = 61)-and compared maternal factors, perinatal factors, neonatal factors, and therapeutic factors between the groups. In addition, home healthcare, readmission, utilization of respite care and home nursing, and cause of death among the survival group were surveyed. Fifty-two (44%) patients with T18 survived at discharge and their 1-year survival rate was 29%. The survival group had a longer gestation period, larger physique, and longer survival time, compared to the death group. Independent factors associated with survival discharge were the absence of an extremely low birthweight infant (ELBWI), the absence of esophageal atresia and patent ductus arteriosus, and cardiovascular surgery. All surviving patients required some home healthcare. The most frequent cause of death was a respiratory disorder. We recommend discussing the treatment strategy with families in the presence of neonatologists or pediatric surgeons, who can explain differences in prognosis, based on the gestation period, birthweight, severity of cardiovascular disease, and cardiovascular surgery.

    DOI: 10.1002/ajmg.a.61146

    Web of Science

    PubMed

  20. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. Reviewed

    Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y, Nagoya Collaborative Clinical Research Team.

    Nagoya journal of medical science   Vol. 81 ( 2 ) page: 227 - 232   2019.5

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Neonates who swallow a considerable amount of maternal blood may exhibit vomiting and suckling disorder during the first few days of the postnatal period. Some clinicians treat these neonates with gastric lavage (GL) to prevent vomiting and the establishment of enteral feeding empirically, but there was no study assessing the effect of GL for neonates with coffee-ground emesis. We designed a multicenter randomized controlled trial to evaluate the efficacy and safety of GL in neonates with coffee-ground emesis. Vigorous neonates with birth weight ranging from 2500 g to 3999 g and gestational age between 37w0d and 41w6d who presented with coffee-ground emesis on more than twice and diagnosed as false melena, were divided into two groups using computerized randomization. We defined feeding intolerance (FI) as (1) ≥2 vomiting episodes in 4h or ≥3 episodes in 24h and/or (2) feeding failure on at least two occasions because of retching or poor sucking. Primary outcome is percentage of infants who present FI within 24 hours from admission. We also assessed the residual volumes, number of vomiting episodes, percentage of weight reduction at postnatal day 4, rates of body weight gain at 1 month of age, and peak serum total bilirubin value before discharge. To our knowledge, this is the first study to evaluate the safety and efficacy of GL for neonates with coffee-ground emesis. This trial is registered at UMIN Clinical Trials Registry as UMIN000026483.

    DOI: 10.18999/nagjms.81.2.227

    Web of Science

    PubMed

  21. Comparison of high-dose and low-dose corticosteroid therapy for refractory Mycoplasma pneumoniae pneumonia in children. Reviewed International journal

    Toshihiko Okumura, Jun-Ichi Kawada, Masaharu Tanaka, Kotaro Narita, Tomonori Ishiguro, Yuji Hirayama, Sho Narahara, Genki Tsuji, Yuichiro Sugiyama, Michio Suzuki, Takeshi Tsuji, Shin Hoshino, Masahiro Nakatochi, Hideki Muramatsu, Hiroyuki Kidokoro, Yoshiyuki Takahashi, Yoshiaki Sato

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   Vol. 25 ( 5 ) page: 346 - 350   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Mycoplasma pneumoniae pneumonia (MPP) is generally a self-limiting disease, but it may become refractory. It is thought that refractory MPP is linked to the excessive immunologic responses of the host. Consequently, the use of adjunctive systemic corticosteroids may have beneficial effects. In this study, we compared the effects of high- and low-dose corticosteroid therapy in a pediatric population with refractory MPP. METHODS: We retrospectively collected data from 91 pediatric MPP patients treated with adjunctive systemic corticosteroids between April 2014 and October 2016. The patients were divided into the following two groups: high-dose corticosteroid group (2 mg/kg/day or more of prednisolone equivalents; n = 38) and low-dose corticosteroid group (<2 mg/kg/day; n = 53). Additionally, we compared the number of febrile days post-corticosteroid administration. We used 25 paired patients in a propensity score matching analysis to correct for confounding factors both by age and by days (from onset till corticosteroid therapy initiation). RESULTS: We observed that in the high-dose corticosteroid group defervescence following corticosteroid therapy initiation was achieved significantly earlier and length of hospitalization was significantly shorter (0.8 ± 1.0 vs. 1.5 ± 1.4 days and 8.2 ± 2.4 vs. 10.7 ± 2.7 days, respectively). In the propensity score matching, we observed that significant differences in the length of fever following corticosteroid therapy initiation and hospitalization were still present. Further, neither of the groups developed corticosteroid-related adverse events. CONCLUSION: Our results suggest that patients with refractory MPP treated with high-dose corticosteroid could achieve defervescence earlier and have a shorter hospitalization.

    DOI: 10.1016/j.jiac.2019.01.003

    Web of Science

    PubMed

  22. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. Reviewed International journal

    Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, Hirakawa A, Kidokoro H, Natsume J, Hayakawa M

    Archives of disease in childhood. Fetal and neonatal edition   Vol. 103 ( 3 ) page: F238 - F244   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: To compare magnetic resonance spectroscopy (MRS) metabolite ratios in preterm infants at term-equivalent age with those in term infants and to evaluate the association between MRS metabolites and neurodevelopmental outcomes at 18 months corrected age in preterm infants. DESIGN: We studied infants born at a gestational age <37 weeks and weighing <1500 g during 2009-2013 using MRS at term-equivalent age. Infants with major brain abnormalities were excluded. The ratios of N-acetylaspartate (NAA) to creatine (Cre), NAA to choline-containing compounds (Cho) and Cho to Cre in the frontal white matter and thalamus were measured using multivoxel point-resolved proton spectroscopy sequence. Neurodevelopmental outcomes were assessed at 18 months corrected age. RESULTS: Thirty-three preterm infants and 16 term infants were enrolled in this study. Preterm infants with normal development at 18 months showed significantly lower NAA/Cho ratios in the frontal white matter than term infants. There were no differences in the Cre/Cho ratios between preterm and term infants. At 18 months corrected age, 9 preterm infants with a mild developmental delay showed significantly lower NAA/Cho ratios in the thalamus than 24 preterm infants with normal development. CONCLUSIONS: Preterm infants at term-equivalent age showed reduced MRS metabolites (NAA/Cho) compared with term infants. Decreased NAA/Cho ratios in the thalamus were associated with neurodevelopmental delay at 18 months corrected age in preterm infants.

    DOI: 10.1136/archdischild-2016-311403

    Web of Science

    PubMed

  23. Successful Infant Pneumonectomy with Unilateral Pulmonary Artery Occlusion Test

    Kato Koji, Kato Taichi, Hayano Satoshi, Fukasawa Yoshie, Numaguchi Atsushi, Hattori Tetsuo, Saito Akiko, Sato Yoshiaki, Hayakawa Masahiro

    International Heart Journal   Vol. 59 ( 1 ) page: 237 - 239   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:International Heart Journal Association  

    <p>The use of unilateral pulmonary artery occlusion (UPAO) test for the preoperative evaluation of pneumonectomy was reported in adult patients. On the contrary, in infants, no strategies have yet been recommended to predict hemodynamics after pneumonectomy, nor has use of the UPAO test been reported. We describe the first case of infant with abnormal pulmonary circulation in whom successful pneumonectomy was performed after preoperative evaluation using UPAO test. Right pneumonectomy was planned for an 8-month-old girl, because of decreased right pulmonary function, high risk of pneumothorax, and impaired left lung expansion due to overexpansion caused by severe left bronchial stenosis and bronchomalacia. However, she had also prolonged pulmonary hypertension and there was difficulty in accurate echocardiographic evaluation of its severity due to concomitant left pulmonary artery stenosis. Furthermore, contrast-enhanced computer tomography suggested a certain degree of right pulmonary venous flow, discordant with the result showing scarce right pulmonary flow in perfusion scintigraphy. Predicting postoperative hemodynamic changes was therefore considered difficult. To evaluate these concerns, we performed cardiac catheterization and UPAO test to simulate postoperative hemodynamics. Pulmonary arteriography showed decreased but significant right pulmonary arterial and venous flows. Measurements including pulmonary artery pressure and cardiac index showed no marked changes after occlusion. Based on UPAO test results, the operation was successfully performed and hemodynamics remained stable postoperatively. The UPAO test may be useful for infants with cardiopulmonary impairment to evaluate the tolerability of pneumonectomy.</p>

    DOI: 10.1536/ihj.16-606

    Web of Science

    PubMed

    CiNii Research

    Other Link: http://orcid.org/0000-0001-6320-9176

  24. Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice. Reviewed International journal

    Tanaka E, Ogawa Y, Mukai T, Sato Y, Hamazaki T, Nagamura-Inoue T, Harada-Shiba M, Shintaku H, Tsuji M

    Frontiers in neurology   Vol. 9   page: 133 - 133   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Frontiers Media S.A.  

    Neonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of intravenously administered human umbilical cord-derived MSCs (UC-MSCs) in neonatal stroke mice. Pups underwent permanent middle cerebral artery occlusion at postnatal day 12 (P12), and low-dose (1 × 104) or high-dose (1 × 105) UC-MSCs were administered intravenously 48 h after the insult (P14). To evaluate the effect of the UC-MSC treatment, neurological behavior and cerebral blood flow were measured, and neuroanatomical analysis was performed at P28. To investigate the mechanisms of intravenously injected UC-MSCs, systemic blood flowmetry, in vivo imaging and human brain-derived neurotrophic factor (BDNF) measurements were performed. Functional disability was significantly improved in the high-dose UC-MSC group when compared with the vehicle group, but cerebral blood flow and cerebral hemispheric volume were not restored by UC-MSC therapy. The level of exogenous human BDNF was elevated only in the cerebrospinal fluid of one pup 24 h after UC-MSC injection, and in vivo imaging revealed that most UC-MSCs were trapped in the lungs and disappeared in a week without migration toward the brain or other organs. We found that systemic blood flow was stable over the 10 min after cell administration and that there were no differences in mortality among the groups. Immunohistopathological assessment showed that the percent area of Iba1-positive staining in the peri-infarct cortex was significantly reduced with the high-dose UC-MSC treatment compared with the vehicle treatment. These results suggest that intravenous administration of UC-MSCs is safe for a mouse model of neonatal stroke and improves dysfunction after middle cerebral artery occlusion by modulating the microglial reaction in the peri-infarct cortex.

    DOI: 10.3389/fneur.2018.00133

    Web of Science

    Scopus

    PubMed

  25. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: A non-inferiority randomized control trial. Reviewed International journal

    Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S

    PloS one   Vol. 13 ( 2 ) page: e0192688   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The aim of this prospective multicenter randomized controlled trial was to compare the efficacy of silver nitrate cauterization against that of topical steroid ointment in the treatment of neonatal umbilical granuloma. METHODS: An open-label, non-inferiority randomized controlled trial was conducted from January 2013 to January 2016. The primary endpoint for the silver nitrate cauterization and topical steroid ointment groups was the healing rate after 2 weeks of treatment, applying a non-inferiority margin of 10%. The healing rate was evaluated until completion of 3 weeks of treatment. RESULTS: Participants comprised 207 neonates with newly diagnosed umbilical granuloma, randomized to receive silver nitrate cauterization (n = 104) or topical steroid ointment (n = 103). Healing rates after 2 weeks of treatment were 87.5% (91/104) in the silver nitrate cauterization and 82% (82/100) in the topical steroid ointment group group. The difference between groups was -5.5% (95% confidence interval, -19.1%, 8.4%), indicating that the non-inferiority criterion was not met. After 3 weeks of treatment, the healing rate with topical steroid ointment treatment was almost identical to that of silver nitrate cauterization (94/104 [90.4%] vs. 91/100 [91.0%]; 0.6% [-13.2 to 14.3]). No major complications occurred in either group. CONCLUSIONS: This study did not establish non-inferiority of topical steroid ointment treatment relative to silver nitrate cauterization, presumably due to lower healing rates than expected leading to an underpowered trial. However, considering that silver nitrate cauterization carries a distinct risk of chemical burns and that the overall efficacy of topical steroid ointment treatment is similar to that of silver nitrate cauterization, topical steroid ointment might be considered as a good alternative in the treatment of neonatal umbilical granuloma due to its safety and simplicity. To clarify non-inferiority, a larger study is needed.

    DOI: 10.1371/journal.pone.0192688

    Web of Science

    PubMed

    Other Link: http://orcid.org/0000-0001-6320-9176

  26. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. Reviewed International journal

    Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, Hirakawa A, Nakanishi K, Tsuji M, Hayakawa M

    Frontiers in neurology   Vol. 9   page: 987 - 987   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background/Objective: Perinatal hypoxic-ischemia (HI) causes neonatal death and permanent neurological deficits. Cell therapy using various cell sources has been recently identified as a novel therapy for perinatal HI. Among the available types of cell sources, bone marrow-derived mononuclear cells (BMMNCs) have unique features for clinical application. For example, stem cells can be collected after admission, thus enabling us to perform autologous transplantation. This study aimed to investigate whether the administration of BMMNCs ameliorated HI brain injury in a neonatal rat model. Methods: Seven-day-old rats underwent left carotid artery ligation and were exposed to 8% oxygen for 60 min. BMMNCs were collected from the femurs and tibias of juvenile rats using the Ficoll-Hypaque technique and injected intravenously 24 h after the insult (1 × 105 cells). Active caspase-3, as an apoptosis marker, and ED1, as an activated microglia/macrophage marker, were evaluated immunohistochemically 48 h after the insult (vehicle, n = 9; BMMNC, n = 10). Behavioral assessments using the rotarod treadmill, gait analysis, and active avoidance tests were initiated 3 weeks after the insult (sham, n = 9, vehicle, n = 8; BMMNC, n = 8). After these behavioral tests (6 weeks after the insult), we evaluated the volumes of their hippocampi, cortices, thalami, striata, and globus pallidus. Results: The mean cell densities of the sum of four parts that were positive for active caspase-3 significantly decreased in the BMMNC group (p < 0.05), whereas in the hippocampi, cortices, thalami, and striata cell densities decreased by 42, 60, 56, and 47%, respectively, although statistical significance was not attained. The number of ED1 positive cells for the sum of the four parts also significantly decreased in the BMMNC group compared to the vehicle group (p < 0.05), whereas in each of the four parts the decrease was 35, 39, 47, and 36%, respectively, although statistical significance was not attained. In gait analysis, the BMMNC normalized the contact area of the affected hind paw widened by HI. The volumes of the affected striata and globus pallidus were significantly larger in the BMMNC group than in the control group. Conclusion: These results indicated that the injection of BMMNCs ameliorated HI brain injury in a neonatal rat model.

    DOI: 10.3389/fneur.2018.00987

    Web of Science

    PubMed

  27. Ureteral dilatation detected in magnetic resonance imaging predicts vesicoureteral reflux in children with urinary tract infection. Reviewed International journal

    Murakami N, Kawada JI, Watanabe A, Arakawa T, Kano T, Suzuki T, Tanaka R, Kojima D, Kawano Y, Hoshino S, Muramatsu H, Takahashi Y, Sato Y, Koyama M, Natsume J

    PloS one   Vol. 13 ( 12 ) page: e0209595   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Urinary tract infection (UTI), one of the most common bacterial infections occurring during infancy and early childhood, is frequently associated with vesicoureteral reflux (VUR). Although several guidelines recommend performing ultrasonography as a screening test, its utility is not adequate and appropriate screening tests are strongly desirable. In this study, we evaluate the use of magnetic resonance imaging (MRI) as a screening test for VUR in children with UTI. METHODS: We prospectively studied 108 patients with suspected UTI between April 2014 and March 2016. UTI was diagnosed on the basis of diffusion-weighted MRI (DW-MRI) and urine culture findings. We measured ureteral dilatation using MRI in 96 patients with UTI and assessed the relationship between ureteral dilatation in MRI and VUR in 46 patients who underwent voiding cystourethrography (VCUG). RESULTS: Among 108 patients, 88 and 8 were diagnosed with upper and lower UTI, respectively. Among 46 patients who underwent VCUG, 23 had VUR (14 low grade and 9 high grade). Patients with ureteral dilatation detected on MRI had VUR more frequently than those without ureteral dilatation (any grades VUR, 71% vs. 32%; P = 0.02; high-grade VUR, 38% vs. 2%, P = 0.007). Overall, ureteral dilatation findings on MRI achieved sensitivity 65.2% and specificity 73.9% as a screening test for VUR. In addition, DW-MRI achieved sensitivity 100% and specificity 81.8% in the diagnosis of upper UTI. CONCLUSION: These findings suggested that MRI is a valuable tool for screening of VUR as well as diagnosis of upper UTI.

    DOI: 10.1371/journal.pone.0209595

    Web of Science

    PubMed

  28. Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cell, but not Adipose Tissue-Derived Stem Cell, Ameliorated the Neonatal Hypoxic-Ischemic Brain Injury by Changing Cerebral Inflammatory State in Rat. Reviewed International journal

    Sugiyama Y, Sato Y, Kitase Y, Suzuki T, Kondo T, Mikrogeorgiou A, Horinouchi A, Maruyama S, Shimoyama Y, Tsuji M, Suzuki S, Yamamoto T, Hayakawa M

    Frontiers in neurology   Vol. 9   page: 757 - 757   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Perinatal hypoxic-ischemic (HI) brain injury occurs in 1 in 1,000 live births and remains the main cause of neurological disability and death in term infants. Cytotherapy has recently emerged as a novel treatment for tissue injury. In particular, mesenchymal stem cells (MSCs) are thought to have therapeutic potential, but little is known about the differences according to their origin. In the current study, we investigated the therapeutic effects and safety of intravenous injection of allogeneic bone marrow-derived MSCs (BM-MSCs) and adipose-derived stem cells (ADSCs) in a rat model of HI brain injury. HI models were generated by ligating the left carotid artery of postnatal day 7 Wistar/ST rats and exposing them to 8% hypoxia for 60 min. Bone marrow and adipose tissue were harvested from adult green fluorescent protein transgenic Wistar rats, and cells were isolated and cultured to develop BM-MSCs and ADSCs. At passaging stages 2-3, 1 × 105 cells were intravenously injected into the external right jugular vein of the HI rats at 4 or 24 h after hypoxia. Brain damage was evaluated by counting the number of cells positive for active caspase-3 in the entire dentate gyrus. Microglial isotypes and serum cytokines/chemokines were also evaluated. Distribution of each cell type after intravenous injection was investigated pathologically and bio-optically by ex vivo imaging (IVIS®) with a fluorescent lipophilic tracer DiR. The mortality rate was higher in the ADSC group compared to the BM-MSC group, in pups injected with cells 4 h after hypoxia. The number of active caspase-3-positive cells significantly decreased in the BM-MSC group, and the percentage of M1 microglia (a proinflammatory isotype) was also lower in the BM-MSC vs control group in the penumbra of the cortex. Moreover, BM-MSC administration increased anti-inflammatory cytokine and growth factor levels, while ADSCs did not. Each injected cell type was mainly distributed in the lungs and liver, but ADSCs remained in the lungs longer. Pathologically, pulmonary embolisms and diffuse alveolar hemorrhages were seen in the ADSC group. These results indicated that injection of allogeneic BM-MSCs ameliorated neonatal HI brain injury, whereas ADSCs induced severe lung hemorrhage and higher mortality.

    DOI: 10.3389/fneur.2018.00757

    Web of Science

    PubMed

  29. Grafting Neural Stem and Progenitor Cells Into the Hippocampus of Juvenile, Irradiated Mice Normalizes Behavior Deficits. Reviewed International journal

    Sato Y, Shinjyo N, Sato M, Nilsson MKL, Osato K, Zhu C, Pekna M, Kuhn HG, Blomgren K

    Frontiers in neurology   Vol. 9   page: 715 - 715   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The pool of neural stem and progenitor cells (NSPCs) in the dentate gyrus of the hippocampus is reduced by ionizing radiation. This explains, at least partly, the learning deficits observed in patients after radiotherapy, particularly in pediatric cases. An 8 Gy single irradiation dose was delivered to the whole brains of postnatal day 9 (P9) C57BL/6 mice, and BrdU-labeled, syngeneic NSPCs (1.0 × 105 cells/injection) were grafted into each hippocampus on P21. Three months later, behavior tests were performed. Irradiation impaired novelty-induced exploration, place learning, reversal learning, and sugar preference, and it altered the movement pattern. Grafting of NSPCs ameliorated or even normalized the observed deficits. Less than 4% of grafted cells survived and were found in the dentate gyrus 5 months later. The irradiation-induced loss of endogenous, undifferentiated NSPCs in the dentate gyrus was completely restored by grafted NSPCs in the dorsal, but not the ventral, blade. The grafted NSPCs did not exert appreciable effects on the endogenous NSPCs; however, more than half of the grafted NSPCs differentiated. These results point to novel strategies aimed at ameliorating the debilitating late effects of cranial radiotherapy, particularly in children.

    DOI: 10.3389/fneur.2018.00715

    Web of Science

    PubMed

  30. Carbamylated Erythropoietin Decreased Proliferation and Neurogenesis in the Subventricular Zone, but Not the Dentate Gyrus, After Irradiation to the Developing Rat Brain. Reviewed International journal

    Osato K*, Sato Y*(*equally contribution), Osato A, Sato M, Zhu C, Leist M, Kuhn HG, Blomgren K

    Frontiers in neurology   Vol. 9   page: 738 - 738   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cranial radiotherapy for pediatric brain tumors causes progressive, debilitating late effects, including cognitive decline. Erythropoietin (EPO) has been shown to be neuroprotective and to promote neuroregeneration. Carbamylated erythropoietin (CEPO) retains the protective properties of EPO but is not erythrogenic. To study the effects of CEPO on the developing brain exposed to radiotherapy, a single irradiation (IR) dose of 6 Gy was administered to the brains of postnatal day 9 (P9) rats, and CEPO (40 μg/kg s.c.) was injected on P8, P9, P11, P13, and P15. To examine proliferation, 5-Bromo-2-deoxyuridine (BrdU) was injected on P15, P16, and P17. CEPO administration did not affect BrdU incorporation in the granule cell layer (GCL) of the hippocampus or in the subventricular zone (SVZ) as quantified 7 days after the last BrdU injection, whereas IR decreased BrdU incorporation in the GCL and SVZ by 63% and 18%, respectively. CEPO did not affect BrdU incorporation in the GCL of irradiated brains, although it was reduced even further (to 31%) in the SVZ. To evaluate the effect of CEPO on neurogenesis, BrdU/doublecortin double-positive cells were quantified. CEPO did not affect neurogenesis in non-irradiated brains, whereas IR decreased neurogenesis by 58% in the dentate gyrus (DG) but did not affect it in the SVZ. In the DG, CEPO did not affect the rate of neurogenesis following IR, whereas in the SVZ, the rate decreased by 30% following IR compared with the rate in vehicle-treated rats. Neither CEPO nor IR changed the number of microglia. In summary, CEPO did not promote neurogenesis in non-irradiated or irradiated rat brains and even aggravated the decreased neurogenesis in the SVZ. This raises concerns regarding the use of EPO-related compounds following radiotherapy.

    DOI: 10.3389/fneur.2018.00738

    Web of Science

    PubMed

  31. Factors related to home health-care transition in trisomy 13. Reviewed International journal

    Kitase Y, Hayakawa M, Kondo T, Saito A, Tachibana T, Oshiro M, Ieda K, Kato E, Kato Y, Hattori T, Hayashi S, Ito M, Hyodo R, Muramatsu Y, Sato Y

    American journal of medical genetics. Part A   Vol. 173 ( 10 ) page: 2635 - 2640   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Trisomy 13 (T13) is accompanied by severe complications, and it can be challenging to achieve long-term survival without aggressive treatment. However, recently, some patients with T13 have been receiving home care. We conducted this study to investigate factors related to home health-care transition for patients with T13.We studied 28 patients with T13 born between January 2000 and December 2014. We retrospectively compared nine home care transition patients (the home care group) and 19 patients that died during hospitalization (the discharge at death group). The median gestational age of the patients was 36.6 weeks, with a median birth weight of 2,047 g. Currently, three patients (11%) have survived, and 25 (89%) have died. The home care group exhibited a significantly longer gestational age (38.9 vs. 36.3 weeks, p = 0.039) and significantly larger occipitofrontal circumference Z score (-0.04 vs. -0.09, p = 0.019). Congenital heart defects (CHD) was more frequent in the discharge at death group, with six patients in the home care group and 18 patients in the discharge at death group (67% vs. 95%, p = 0.047), respectively. Survival time was significantly longer in the home care group than in the discharge at death group (171 vs. 19 days, p = 0.012). This study has shown that gestational age, occipitofrontal circumference Z score at birth, and the presence of CHD are helpful prognostic factors for determining treatment strategy in patients with T13.

    DOI: 10.1002/ajmg.a.38371

    Web of Science

    PubMed

  32. A new type of swaddling clothing improved development of preterm infants in neonatal intensive care units. Reviewed International journal

    Kitase Y, Sato Y, Takahashi H, Shimizu M, Ishikawa C, Yamamoto H, Hayakawa M

    Early human development   Vol. 112   page: 25 - 28   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER IRELAND LTD  

    BACKGROUND: Preterm infants undergo stress owing to essential treatments and exposure to the extrauterine environment in neonatal intensive care units. AIMS: The aim of this study was to enable preterm infants to maintain adequate positioning with a newly developed swaddling clothing, in order to improve low muscle tone and sleep quality, and to confirm the safety of the clothing. STUDY DESIGN: This prospective clinical trial included an intervention group (preterm infants wearing bag-shaped clothing, allowing only exposure of the head, n=27), and a control group (preterm infants managed only with conventional swaddling, n=12). OUTCOME MEASURES: We used the Dubowitz method to analyze behavior, recorded the frequency of vomiting and apnea in both groups, and assessed the sleep state in the intervention group. RESULTS: Muscle tone and total score for the Dubowitz method significantly improved in the intervention group, compared with those in the control group. We evaluated the sleep state before and after the introduction of the device in the intervention group, and State 1 increased from 53.5% to 69.2% after introduction. No significant difference was seen in the frequency of vomiting and apnea between the groups. CONCLUSIONS: The new swaddling clothing with enhanced stretch capacity improved the muscle tone and increased sleep time by decreasing the state level of preterm infants. This is an effective tool to assist in infant development in neonatal intensive care units.

    DOI: 10.1016/j.earlhumdev.2017.06.005

    Web of Science

    PubMed

  33. The relationship between three signs of fetal magnetic resonance imaging and severity of congenital diaphragmatic hernia Reviewed

    Hattori T, Hayakawa M, Ito M, Sato Y, Tamakoshi K, Kanamorit Y, Okuyama H, Inannura N, Takahashi S, Fujino Y, Taguchi T, Usui N.

    JOURNAL OF PERINATOLOGY   Vol. 37 ( 3 ) page: 265 - 269   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    OBJECTIVE: To seek a simple approach for prenatally classifying congenital diaphragmatic hernia (CDH) severity using fetal magnetic resonance imaging (MRI) markers.
    STUDY DESIGN: A retrospective, multicenter study using questionnaires to investigate fetal MRI findings. We included fetuses prenatally diagnosed with isolated left-sided CDH and delivered after 36 weeks of gestation. We focused on three fetal MRI morphological signs: incomplete pulmonary baseline (IPB), liver up (LU) and retrocardiac stomach (RCS). We also evaluated the fetal MRI score defined as the total number of positive signs; the primary outcome was survival at discharge.
    RESULTS: In 256 patients (from 56 institutions), IPB, LU and RCS findings correlated with lower survival: odds ratio (95% confidence interval), 0.16 (0.08 to 0.33); 0.24 (0.12 to 0.51); and 0.14 (0.07 to 0.28); respectively. Patients with higher fetal MRI scores had a higher mortality rate.
    CONCLUSION: IPB, LU and RCS on fetal MRI are related to CDH severity.

    DOI: 10.1038/jp.2016.208

    Web of Science

    Other Link: http://orcid.org/0000-0001-6320-9176

  34. Dedifferentiated Fat Cells as a Novel Source for Cell Therapy to Target Neonatal Hypoxic-Ischemic Encephalopathy

    Mikrogeorgiou A, Sato Y, Kondo T, Hattori T, Sugiyama Y, Ito M, Saito A, Nakanishi K, Tsuji M, Kazama T, Kano K, Matsumoto T, Hayakawa M

    Dev Neurosci   Vol. 39   page: 273-286   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000455836

  35. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats

    Nakanishi K, Sato Y, Mizutani Y, Ito M, Hirakawa A, Higashi Y.

    Sci Rep   Vol. 7   page: 44111   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/srep44111

  36. Abnormal urinalysis on day 7 in patients with IgA vasculitis (Henoch-Schonlein purpura)

    Kawashima N, Kawada J, Nishikado Y, Kitase Y, Ito S, Muramatsu H, Sato Y, Kato T, Natsume J, Kojima S.

    Nagoya J Med Sci   Vol. 78 ( 4 ) page: 359-368   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.78.4.359

  37. Mild intrauterine hypoperfusion reproduces neurodevelopmental disorders observed in prematurity

    Ohshima M, Coq JO, Otani K, Hattori Y, Ogawa Y, Sato Y, Harada-Shiba M, Ihara M, Tsuji M.

    Sci Rep   Vol. 6   page: 39377   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/srep39377

  38. Evaluations of Intravenous Administration of CD34+ Human Umbilical Cord Blood Cells in a Mouse Model of Neonatal Hypoxic-Ischemic Encephalopathy

    Ohshima M, Taguchi A, Sato Y, Ogawa Y, Saito S, Yamahara K, Ihara M, Harada-Shiba M, Ikeda T, Matsuyama T, Tsuji M

    Dev Neurosci   Vol. 38 ( 5 ) page: 331 - 341   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000454830

    PubMed

  39. TREC定量による重症複合免疫不全症の新生児マススクリーニング Reviewed

    小島大英、杉山裕一朗、村松秀城、近藤大貴、安井正宏、木戸真二、佐藤義朗、早川昌弘、小島勢二

    日本小児科学会雑誌   Vol. 120 ( 10 ) page: 1462-1467   2016

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  40. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes

    Futamura Y, Asami T, Nonobe N, Kachi S, Ito Y, Sato Y, Hayakawa M, Terasaki H.

    Jpn J Ophthalmol   Vol. 59 ( 6 ) page: 378-88   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10384-015-0401-5

  41. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats

    Hattori T*, Sato Y*(*equally contribution), Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T., Hirata H, Hirakawa A, Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M.

    Dev Neurosci   Vol. 37 ( 2 ) page: 95-104   2015

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000368396

  42. Maternal molecular hydrogen treatment attenuates lipopolysaccharide-induced rat fetal lung injury

    Hattori Y, Kotani T, Tsuda H, Mano Y, Tu L, Li H, Hirako S, Ushida T, Imai K, Nakano T, Sato Y, Miki R, Sumigama S, Iwase A, Toyokuni S, Kikkawa F.

    Free Radic Res   Vol. 49 ( 8 ) page: 1026-37   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/10715762.2015.1038257

  43. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury

    Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y, Iwase A, Hirakawa A, Asai M, Toyokuni S, Kikkawa F.

    J Clin Biochem Nutr   Vol. 57 ( 3 ) page: 178-82   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3164/jcbn.15-90

  44. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia

    Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, Miyazato M, Ikeda T, Iida H, Tsuji M.

    Brain Dev   Vol. 37 ( 4 ) page: 376-86   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.braindev.2014.06.010

  45. Multicenter observational study comparing sedation/analgesia protocols for laser photocoagulation treatment of retinopathy of prematurity

    Sato Y, Oshiro M, Takemoto K, Hosono H, Saito A, Kondo T, Aizu K, Matsusawa M, Futamura Y, Asami T, Terasaki H, Hayakawa M.

    J Perinatol   Vol. 35 ( 11 ) page: 965-9   2015

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/jp.2015.112

  46. Paradoxical downward seizure pattern on amplitude-integrated electroencephalogram Reviewed

    Ito M, Kidokoro H, Sugiyama Y, Sato Y, Natsume J, Watanabe K, Hayakawa M.

    J Perinatol   Vol. 34 ( 8 ) page: 642-4   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  47. Effects of intravenous administration of umbilical cord blood CD34 cells in a mouse model of neonatal stroke Reviewed

    Tsuji M. Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, Otani K, Yamahara K, Ihara M, Harada-Shiba M, Ikeda T, Matsuyama T.

    Neuroscience   Vol. 263C   page: 148-158   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  48. Effect of placenta previa on neonatal respiratory disorders and amniotic lamellar body counts at 36-38weeks of gestation Reviewed

    Tsuda H, Kotani T, Sumigama S, Mano Y, Hua L, Hayakawa H, Hayakawa M, Sato Y, Kikkawa F.

    Early Hum Dev   Vol. 90 ( 1 ) page: 51-4   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  49. Amniotic lamellar body count and congenital diaphragmatic hernia in humans and in a rat model Reviewed

    Watanabe Y, Tsuda H, Kotani T, Sumigama S, Mano Y, Hayakawa M, Sato Y, Kikkawa F.

    Pediatr Res   Vol. 73 ( 3 ) page: 344-8   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  50. Grafting of neural stem and progenitor cells to the hippocampus of young, irradiated mice causes gliosis and disrupts the granule cell layer Reviewed

    Sato Y, Shinjyo N, Sato M, Osato K, Zhu C, Pekna M, Kuhn HG, Blomgren K.

    Cell Death Dis   Vol. 4   page: e591   2013

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  51. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates Reviewed

    Sato Y, Kawataki M, Hirakawa A, Toyoshima K, Kato T, Itani Y, Hayakawa M.

    Acta Paediatr   Vol. 102 ( 6 ) page: e241-6   2013

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

  52. Dexamethasone administration to the neonatal rat results in neurological dysfunction at the juvenile stage even at low doses Reviewed

    Ichinohashi Y, Sato Y, Saito A, Ito M, Watanabe K, Hayakawa M, Nakanishi K, Wakatsuki A, Oohira A.

    Early Hum Dev   Vol. 89 ( 5 ) page: 283-8   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  53. Astroglial IFITM3 mediates neuronal impairments following neonatal immune challenge in mice. Reviewed

    Ibi D, Nagai T, Nakajima A, Mizoguchi H, Kawase T, Tsuboi D, Kano S, Sato Y, Hayakawa M, Lange UC, Adams DJ, Surani MA, Satoh T, Sawa A, Kaibuchi K, Nabeshima T, Yamada K.

    Glia   Vol. 61 ( 5 ) page: 679   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/glia.22461

  54. A highly-sulfated chondroitin sulfate, CS-E, adsorbs specifically to neurons with nuclear condensation. Reviewed

    Nakanishi K, Ito M, Sato Y, Oohira A.

    Neuroscience research   Vol. 74   page: 223-239   2012

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.neures.2012.08.009

  55. Congenital pancreatoblastoma associated with beta-catenin mutation Reviewed

    Ismael O, Shimada A, Hama A, Takahashi Y, Sato Y, Hayakawa M, Tsuchiya H, Tainaka T, Ono Y, Kaneko K, Ando H, Sato K, Kojima S.

    Pediatric blood & cancer.   Vol. 58 ( 5 ) page: 827   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  56. Carbohydrate and energy metabolism in the brain of rats with thromboxane A2-induced fetal growth restriction. Reviewed

    Hayakawa M, Sato Y, Hattori T, Ichinohashi Y, Nakayama A, Yamamoto H, Hemmi H, Ito M, Ieda K, Kojima S.

    Pediatr Res.   Vol. 70 ( 1 ) page: 21-4   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  57. Biological activities of highly sulfated chondroitin sulfate polysaccharides on neural cells. Reviewed

    Nakanishi K, Sato Y, Oohira A.

    Research Advances in Neurochemistry, Global Research Network   Vol. 1   page: 1-10   2010

     More details

    Language:English  

  58. The diffusion weighted imaging for an early diagnosis of parasagittal injury Reviewed

    Tagaya M, Sato Y, Hayakawa M.

    Pediatr Int.   Vol. 52 ( 2 ) page: 298-301   2010

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  59. Apoptosis-inducing factor deficiency decreases the proliferation rate and protects the subventricular zone against ionizing radiation Reviewed

    Osato, K.*Sato, Y.*(*equally contribution)Ochiishi,T.Osato, A.Zhu, C.Sato, M.Swanpalmer, J.Modjtahedi, N.Kroemer, G.Kuhn, H. G.Blomgren, K.

    Cell Death & Disease   Vol. 1   page: e84   2010

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  60. *Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification. Invited Reviewed

    Sato Y, Oohira A.

    Curr Stem Cell Res Ther   Vol. 4 ( 3 ) page: 200-209   2009

     More details

    Authorship:Lead author, Last author   Language:English  

  61. Male gender is related to the development of parenteral nutrition-associated cholestasis in neonates Reviewed

    Takemoto K, Nakayama A, Ito M, Sato Y, Saito A, Tori Y, Kaneko K, Ando H, Hayakawa M.

    Journal of Neonatal-Perinatal Medicine   Vol. 2 ( 4 ) page: 247-251   2009

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  62. Behavioral abnormalities of fetal growth retardation model rats with reduced amounts of brain proteoglycans. Reviewed

    Saito A, Matsui F, Hayashi K, Watanabe K, Ichinohashi Y, Sato Y, Hayakawa M, Kojima S, Oohira A.

    Exp Neurol   Vol. 219 ( 1 ) page: 81-92   2009

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  63. A highly sulfated chondroitin sulfate preparation, CS-E, prevents excitatory amino acid-induced neuronal cell death. Reviewed

    Sato Y, Nakanishi K, Tokita Y, Kakizawa H, Ida M, Maeda H, Matsui F, Aono S, Saito A, Kuroda Y, Hayakawa M, Kojima S, Oohira A.

    J Neurochem   Vol. 104   page: 1565-1576   2008

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  64. Delayed neurological signs following isolated parasagittal injury in asphyxia at term. Reviewed

    Sato Y, Hayakawa M, Iwata O, Okumura A, Kato T, Hayakawa F, Kubota T, Maruyama K, Hasegawa M, Sato M, Oshiro M, Kito O, Kojima S.

    Eur J Paediatr Neurol   Vol. 12 ( 5 ) page: 359-365   2008

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

  65. Reduction of brain injury in neonatal hypoxic-ischemic rats by intracerebroventricular injection of neural stem/progenitor cells together with chondroitinase ABC. Reviewed

    Sato Y, Nakanishi K, Hayakawa M, Kakizawa H, Saito A, Kuroda Y, Ida M, Tokita Y, Aono S, Matsui F, Kojima S, Oohira A.

    Reprod Sci   Vol. 15 ( 6 ) page: 613-620   2008

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  66. A new method of blood sampling reduces pain for newborn infants: a prospective, randomized controlled clinical trial. Reviewed

    Sato Y, Fukasawa T, Hayakawa M, Yatsuya H, Hatakeyama M, Ogawa A, Kuno K.

    Early Hum Dev   Vol. 83   page: 389-394   2007

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

  67. Novel SLC12A1 (NKCC2) mutations in two families with Bartter syndrome type 1. Reviewed

    Adachi M, Asakura Y, Sato Y, Tajima T, Nakajima T, Yamamoto T, Fujieda K.

    Endocr J   Vol. 54   page: 1003-1007   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  68. The MRI findings of the right-sided fetal lung can be used to predict postnatal mortality and the requirement for extracorporeal membrane oxygenation in isolated left-sided congenital diaphragmatic hernia. Reviewed

    Hayakawa M, Seo T, Itakua A, Hayashi S, Miyauchi M, Sato Y, Saito A, Nakayama A, Takemoto K, Hasegawa M, Kaneko K, Okada M, Hayakawa H, Sumigama S, Kikkawa F, Ando H, Kojima S.

    Pediatr Res   Vol. 62   page: 93-97   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  69. Neuroprotective effect of nipradilol, an NO donor, on hypoxic-ischemic brain injury of neonatal rats. Reviewed

    Kakizawa H, Matsui F, Tokita Y, Hirano K, Ida M, Nakanishi K, Watanabe M, Sato Y, Okumura A, Kojima S, Oohira A.

    Early Hum Dev   Vol. 83   page: 535-540   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  70. Magnetic resonance imaging regional T1 abnormalities at term accurately predict motor outcome in preterm infants. Reviewed

    Nanba Y, Matsui K, Aida N, Sato Y, Toyoshima K, Kawataki M, Hoshino R, Ohyama M, Itani Y, Goto A, Oka A.

    Pediatrics   Vol. 120   page: e10-e19   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  71. An animal model of intrauterine growth retardation induced by synthetic thromboxane a(2). Reviewed

    Hayakawa M, Takemoto K, Nakayama A, Saito A, Sato Y, Hasegawa M, Ieda K, Mimura S.

    J Soc Gynecol Investig   Vol. 13   page: 566-572   2006

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  72. 脳室周囲白質軟化症の発症頻度と胎児発育の関係 Reviewed

    佐藤義朗, 松井潔, 難波由喜子, 猪谷泰史, 山中美智子

    日本周産期・新生児医学会雑誌   Vol. 41 ( 1 ) page: 2000   2005

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  73. Hypoxic ischemic encephalopathy associated with neonatal seizures without other neurological abnormalities. Reviewed

    Sato Y, Okumura A, Kato T, Hayakawa F, Kuno K, Watanabe K.

    Brain Dev   Vol. 25   page: 215-219   2003

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  74. 新しい奇形症候群父性片親ダイソミー14(paternal UPD14) Reviewed

    黒澤健司、五十嵐葉子、佐藤義朗、星野陸夫、山中美智子、西村玄

    こども医療センター医学誌   Vol. 32 ( 3 ) page: 123-125   2003

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  75. 胎児期より管理した新生児Bartter syndromeの1例 Reviewed

    佐藤義朗、菅原智香、難波由喜子、豊島勝昭、松井潔、星野陸夫、大山牧子、川滝元良、山中美智子、猪谷泰史、後藤彰子

    日本新生児学会雑誌   Vol. 39 ( 1 ) page: 52-57   2003

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  76. Paternal UPD14 is responsible for a distinctive malformation complex. Reviewed

    Kurosawa K, Sasaki H, Sato Y, Yamanaka M, Shimizu M, Ito Y, Okuyama T, Matsuo M, Imaizumi K, Kuroki Y, Nishimura G.

    Am J Med Genet   Vol. 110   page: 268-272   2002

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  77. 極低出生体重児における左室壁応力・心筋短縮速度の経時的変化と肺出血・脳室内出血・脳室周囲白質軟化症の関連性について Reviewed

    豊島勝昭、川滝元良、佐藤義朗、難波由喜子、松井潔、星野陸夫、大山牧子、猪谷泰史、後藤彰子、康井制洋、中澤誠

    日本未熟児新生児学会雑誌   Vol. 14 ( 2 ) page: 45-52   2002

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  78. Hypocarbia in preterm infants with periventricular leukomalacia: the relation between hypocarbia and mechanical ventilation. Reviewed

    Okumura A, Hayakawa F, Kato T, Itomi K, Maruyama K, Ishihara N, Kubota T, Suzuki M, Sato Y, Kuno K, Watanabe K.

    Pediatrics   Vol. 107   page: 469-475   2001

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  79. 小児呼吸器感染症における肺炎クラミジアの関与 Reviewed

    宮島雄二、佐藤義朗、鈴木基正、石原尚子、久保田哲夫、加藤徹、山本光章、小川昭正、久野邦義

    日本小児科学会雑誌.   Vol. 104 ( 3 ) page: 351-356   2000

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  80. 小児の肺炎クラミジア感染症と肺炎マイコプラズマ感染症の比較検討 Reviewed

    宮島雄二、城所博之、佐藤義朗、鈴木基正、久保田哲夫、加藤徹、山本光章、小川昭正、久野邦義

    日本小児科学会雑誌.   Vol. 104 ( 7 ) page: 723-729   2000

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Books 6

  1. 今日の治療指針

    ( Role: Contributor)

    2022.1 

     More details

    Total pages:2151   Responsible for pages:1429  

  2. Cell Therapy for Perinatal Brain Injury

    Yoshiaki Sato( Role: Contributor ,  Other tissues-derived mesenchymal stem cells for perinatal brain injury)

    Springer  2018.3 

     More details

    Total pages:150   Responsible for pages:69-76  

  3. Cell Therapy for Perinatal Brain Injury

    Yoshiaki Sato( Role: Contributor ,  Neural stem/progenitor cells for perinatal brain injury)

    Springer  2018.3 

     More details

    Total pages:150   Responsible for pages:37-43  

  4. 今日の治療指針

    ( Role: Contributor)

    2018.1 

  5. 周産期医学必修知識第8版

    佐藤義朗( Role: Contributor ,  新生児編 脳室周囲白質軟化症)

    東京医学社  2016.12 

     More details

    Responsible for pages:718-721  

  6. 小児疾患診療のための病態生理2 改訂第5版

    佐藤義朗( Role: Contributor ,  新生児疾患 脳室周囲白質軟化症)

    東京医学社  2015.11 

     More details

    Responsible for pages:108-113  

▼display all

MISC 18

  1. 【周産期診療の新しい方向性】中枢神経疾患に対する幹細胞療法の展開

    佐藤 義朗

    小児外科   Vol. 7   page: 684-688   2021.7

     More details

    Language:Japanese  

  2. Muse細胞製品(CL2020)を用いた新生児低酸素性虚血脳症に対する医師主導治験 Invited

    佐藤義朗

    愛知県小児科医会会報   Vol. 113   page: 3 - 8   2021.6

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publisher:愛知県小児科医会  

  3. Muse細胞を用いた新生児低酸素性虚血性脳症の新規治療法開発~動物実験から探索的臨床試験(医師主導治験) まで~ Invited

    佐藤義朗

    日本周産期・新生児医学会雑誌   Vol. 56 ( 4 ) page: 1194 - 1197   2021.4

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese  

  4. 低酸素性虚血性脳症治療薬 Invited

    神澤孝洋 佐藤義朗

    周産期医学   Vol. 50   page: 366 - 369   2021.3

     More details

    Language:Japanese  

  5. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    日本新生児成育医学会雑誌   Vol. 33 ( 1 ) page: 41 - 46   2021.2

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese  

  6. 臍帯血幹細胞による細胞療法・再生医療 Invited

    上田一仁 佐藤義朗 早川昌弘

    臨床婦人科産科   Vol. 74 ( 10 ) page: 1062 - 1067   2021.1

     More details

    Language:Japanese  

  7. Stem cell therapy for neonatal diseases Invited

    Sato Yoshiaki

    Journal of Japan Society of Perinatal and Neonatal Medicine   Vol. 57 ( 2 ) page: 234 - 242   2021

     More details

    Language:Japanese  

  8. 【新生児の薬物療法-update】 抗てんかん薬

    佐藤 義朗

    周産期医学   Vol. 2   page: 199-201   2018.2

     More details

    Language:Japanese  

  9. 新生児医療最新トピックNEXT(no.2) 周産期脳障害に対する幹細胞療法

    佐藤 義朗

    Neonatal Care   Vol. 5   page: 457   2017.5

     More details

    Language:Japanese  

  10. 正常からの逸脱をどう考えるか 低血糖を呈する遅発性・進行性周産期脳障害

    佐藤 義朗

    日本母乳哺育学会雑誌   Vol. 1   page: 101-106   2015.7

     More details

    Language:Japanese  

  11. 成熟児のasphyxiaとcerebral palsy その疫学と治療/予後 出生前・出生時は軽微な異常だが、遅発性・進行性の症状を呈する周産期脳障害

    佐藤義朗 岩田欧介 加藤 徹 早川文雄 久保田哲夫 丸山幸一 長谷川正幸 大城誠 鬼頭 修 奥村彰久 早川昌弘

    周産期学シンポジウム   Vol. 31   page: 83-86   2013.11

     More details

    Language:Japanese  

  12. 未熟児網膜症に対する光凝固術施行時の鎮痛・鎮静

    佐藤 義朗 大城 誠 竹本 康二 細野 治樹 齊藤 明子 近藤 大貴 会津 研二 松沢 麻衣子 二村 裕紀子 寺崎 浩子 早川 昌弘

    周産期学シンポジウム   Vol. 29   page: 109-114   2011.11

     More details

    Language:Japanese  

  13. 周産期脳障害に対する幹細胞療法

    佐藤 義朗

    周産期医学   Vol. 11   page: 1531-1536   2011

     More details

    Language:Japanese  

  14. 中枢神経疾患に対する幹細胞療法

    佐藤義朗 中西圭子 服部哲夫 一ノ橋祐子 Blomgren K 大平敦彦 早川昌弘

    脳と発達   Vol. 43 ( 3 ) page: 33-37   2011

     More details

    Language:Japanese  

  15. 新生児代表的疾患の基礎理解(第5回) 脳室内出血(IVH)

    佐藤 義朗

    こどもケア   Vol. 4 ( 5 ) page: 85-91   2009.12

     More details

    Language:Japanese  

  16. 【新生児の薬物療法】 各疾患への薬物療法 新生児痙攣に対するフェノバルビタール療法

    佐藤義朗 早川昌弘

    周産期医学   Vol. 39 ( 12 ) page: 1687-1690   2009.12

     More details

    Language:Japanese  

  17. 神経幹細胞を用いた新生児低酸素性虚血性脳症治療の可能性. Invited

    伊田みちる、 佐藤義朗、大平敦彦

    日本周産期・新生児医学会雑誌   Vol. 44 ( 4 ) page: 872-876   2008

     More details

    Language:Japanese  

  18. 超音波パワードップラーが有用であった急性巣状細菌性腎炎の1例

    佐藤義朗 鈴木基正 加藤徹 山本光章 宮島雄二 小川昭正 久野邦義

    小児科   Vol. 42 ( 8 ) page: 1322-1326   2001

     More details

    Language:Japanese  

▼display all

Presentations 81

  1. Muse細胞を用いた周産期脳障害の新規治療法開発~探索的臨床試験(医師主導治験)~ Invited

    佐藤義朗

    革新的医療技術創出拠点 令和3年度成果報告会  2022.2.21 

     More details

    Event date: 2022.2

    Language:Japanese   Presentation type:Poster presentation  

  2. 周産期疾患に対する幹細胞療法~動物実験から臨床試験まで~ Invited

    佐藤義朗

    令和3年度香川県新生児医療症例検討会  2022.2.19 

     More details

    Event date: 2022.2

    Language:Japanese  

  3. 周産期難治性疾患に対する幹細胞療法の開発~私が基礎研究を始めたわけ、ラボの立ち上げから医師主導治験まで~ Invited

    佐藤義朗

    北海道小児先進医療研究会  2021.11.9 

     More details

    Event date: 2021.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:旭川  

  4. 周産期脳障害に対する幹細胞療法/再生医療の現状と今後の展望 Invited

    佐藤義朗

    第24回⽇本脳低温療法・体温管理学会学術集会  2021.9.26 

     More details

    Event date: 2021.9

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:Web  

  5. Muse細胞を用いた周産期疾患に対する治療法開発~幹細胞療法は新たな“希望の光”となり得るか?~ Invited

    佐藤義朗

    第28回日本排尿機能学会 

     More details

    Event date: 2021.9

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:松本  

  6. 新生児の肺障害を修復する多能性幹細胞(Muse細胞)を用いた再生治療の開発 Invited

    佐藤義朗

    令和3年度AMED再生・細胞医療・遺伝子治療研究開発交流会  2021.9.8 

     More details

    Event date: 2021.9

    Language:Japanese   Presentation type:Poster presentation  

    Venue:Web  

  7. Development of a novel therapy for perinatal brain injury using Muse cells as a regenerative treatment: from animal experiments to a clinical trial Invited International conference

    Yoshiaki Sato

    4th Asia Neonatal Symposium & 8th Shanghai Neonatal Forum  2021.7.17 

     More details

    Event date: 2021.7

    Language:English   Presentation type:Oral presentation (invited, special)  

    Venue: Shanghai   Country:China  

  8. Muse細胞を用いた周産期疾患に対する治療法開発~幹細胞療法は新たな“希望の光”となり得るか?~ Invited

    佐藤義朗

    第57回日本周産期・新生児学会  2021.7.11 

     More details

    Event date: 2021.7

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  9. NICUに於けるワンランク上の呼吸管理戦略 明日から使えるTIPS Invited

    佐藤義朗

    新生児成育セミナー東海 

     More details

    Event date: 2021.6 - 2021.7

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  10. Development of novel therapies for bronchopulmonary dysplasia and perinatal brain injury using multilineage-differentiating stress-enduring cells, as regenerative treatments Invited International conference

    Yoshiaki Sato

    The PAS 2021 Virtual Meeting   2021.5.2 

     More details

    Event date: 2021.4 - 2021.5

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Country:United States  

  11. 新生児低酸素性虚血性脳症に対する幹細胞療法の開発~動物実験から臨床試験まで~ Invited

    佐藤義朗

    第124回日本小児科学会学術集会  2021.4.16 

     More details

    Event date: 2021.4

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  12. Fetal growth restriction induces glucose intolerance and impaired islet morphology in catch-up growth in male rats

    2021.4.16 

     More details

    Event date: 2021.4

    Language:English   Presentation type:Oral presentation (general)  

  13. 胎児発育不全に伴う脳発達異常の早期診断法確立に向けたバイオマーカーの探索

    小野田淳人、北瀬悠磨、辻雅弘、上田一仁、高橋義行、早川昌弘、佐藤義朗

    第124回日本小児科学会学術集会  2021.4.16 

     More details

    Event date: 2021.4

    Language:Japanese   Presentation type:Oral presentation (general)  

  14. Development of novel stem cell therapies for perinatal brain injury Invited

    Yoshiaki Sato

    2021.3.28 

     More details

    Event date: 2021.3

    Language:English   Presentation type:Symposium, workshop panel (public)  

  15. 修復幹細胞(Muse細胞)を用いた低酸素性虚血性脳症に対する新規治療法開発 Invited

    佐藤義朗

    第3回愛知県新生児医療スキルアップ研修会  2021.3.14 

     More details

    Event date: 2021.3

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  16. 胎児発育不全に伴う脳発達異常の新規治療法確立に向けた基礎研究:Muse細胞による改善効果

    小野田淳人、北瀬悠磨、辻雅弘、上田一仁、早川昌弘、佐藤義朗

    第20回日本再生医療学会総会  2021.3.11 

     More details

    Event date: 2021.3

    Language:Japanese   Presentation type:Oral presentation (general)  

  17.  Muse細胞を用いた周産期脳障害の新規治療法開発~探索的臨床試験(医師主導治験)~

    佐藤義朗

    革新的医療技術創出拠点令和二年度成果報告会  2021.3.4 

     More details

    Event date: 2021.3

    Language:Japanese   Presentation type:Poster presentation  

  18. Development of a novel treatment for neonatal brain injuries by Multilineage-differentiating stress-enduring cells—Exploratory investigator-initiated clinical trial— International conference

    Yoshiaki Sato, Shinobu Shimizu, Kazuto Ueda, Toshihiko Suzuki, Ryosuke Miura, Shoji Go, Sakiko Arai, Yuma Kitase, Atsuto Onoda, Masahiro Tsuji, Masahiro Hayakawa

    12th Hershey Conference Series on Developmental Brain Injury: Hypoxic-Ischemic Encephalopathy  2021.2.25 

     More details

    Event date: 2021.2

    Language:English   Presentation type:Poster presentation  

  19. 新生児の肺障害を修復する多能性幹細胞(Muse細胞)を用いた再生治療の開発 Invited

    佐藤義朗、清水忍

    令和2年度 AMED 再生・細胞医療・遺伝子治療研究開発交流会  2021.1.19 

     More details

    Event date: 2021.1

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  20. 周産期脳障害に対する幹細胞療法の開発~脳性麻痺撲滅を目指して~ Invited

    佐藤義朗

    第31回日本小児整形外科学会学術集会  2020.12.3 

     More details

    Event date: 2020.12

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

  21. SHIELD試験の立ち上げ:低体温療法を実施した新生児低酸素性虚血性脳症に対するCL2020の安全性及び忍容性を検討する用量漸増臨床試験

    松山奈央、清水忍、片山朱美、平川晃弘、安藤昌彦、上田一仁、鈴木俊彦、佐藤義朗

    第41回日本臨床薬理学会学術総会  2020.12.3 

     More details

    Event date: 2020.12 - 2020.1

    Language:Japanese   Presentation type:Poster presentation  

  22. Muse細胞を用いた新生児低酸素性虚血性脳症の新規治療法開発~動物実験から探索的臨床試験(医師主導治験)まで~ Invited

    佐藤義朗

    第56回日本周産期・新生児医学会学術集会  2020.11.28 

     More details

    Event date: 2020.11 - 2020.12

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  23. 胎児発育不全(胎児慢性低灌流)による脳障害に対する幹細胞療法 Invited

    佐藤義朗

    超早産児神経発達症研究会   2020.8.2 

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

  24. Identification of biomarkers for early prediction of abnormal brain development following fetal growth restriction

    第43回日本神経科学大会  2020.7.29 

     More details

    Event date: 2020.7 - 2020.8

    Language:English  

  25. Muse細胞を用いた新生児低酸素性虚血性脳症の新規治療法開発~探索的臨床試験(医師主導治験)~

    佐藤義朗 上田一仁 清水忍 鈴木俊彦 呉尚治 三浦良介 新井紗記子 橋本佑樹 本部和也 青山藍子 谷口顕信 棚橋義浩 伊藤美春 齊藤明子 村松友佳子 城所博之 早川昌弘

    第41回日本炎症・再生医学会  2020.7.8 

     More details

    Event date: 2020.7

    Language:Japanese   Presentation type:Poster presentation  

  26. Muse細胞を用いた新生児低酸素性虚血性脳症に対する新規治療法の開発 Invited

    佐藤義朗

    第19回日本再生医療学会総会  2020.5.18 

     More details

    Event date: 2020.5

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  27. 新生児低酸素性虚血性脳症と低体温療法に対して、免疫不全(SCID)マウスはどのような脳障害を呈するのか?

    辻雅弘、田中えみ、佐藤義朗、小川優子 

    第124回日本小児科学会学術集会  2020.4.16 

     More details

    Event date: 2020.4

    Language:Japanese   Presentation type:Oral presentation (general)  

  28. 新生児モデルを用いたドップラーセンサによる心拍測定実験

    上林真司 佐藤里咲 坂口彰浩 佐藤菜津子 佐藤義朗

    2020年電子情報通信学会総合大会  2020.3.17 

     More details

    Event date: 2020.3

    Language:Japanese  

  29. Muse 細胞を用いた低酸素性虚血性脳症に対する新規治療法の開発~より有効で、より多くの患児への幹細胞療法/ 再生医療確立を目指して~ Invited

    佐藤義朗

    第64回日本新生児成育医学会・学術集会 

     More details

    Event date: 2019.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:鹿児島  

  30. Development of a novel treatment for neonatal bronchopulmonary dysplasia by multilineage-differentiating stress-enduring cells International conference

    Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Shoji Go, Kazuto Ueda, Haruka Mimatsu, Yuma Kitase, Hidenori Yamamoto, Taichi Kato, Masahiro Hayakawa

    The 3rd Taiwan-Korea-Japan Joint Congress on Neonatology  2019.11.27 

     More details

    Event date: 2019.11

    Language:English   Presentation type:Poster presentation  

  31. 新生児/小児肺高血圧症に対する幹細胞療法 Invited

    佐藤義朗

    第55回日本小児循環器学会総会・学術集会 

     More details

    Event date: 2019.6

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:札幌  

  32. Stem cell therapy for hypoxic ischemic encephalopathy Invited International conference

    Yoshiaki Sato

    The 7th Shanghai Neonatal Forum 

     More details

    Event date: 2019.6

    Language:English   Presentation type:Oral presentation (invited, special)  

    Venue: Shanghai   Country:China  

  33. これから応用される研究は確実なステップを踏んでいるのか? Invited

    佐藤義朗、清水忍

    第61回日本小児神経学会学術集会 

     More details

    Event date: 2019.5 - 2019.6

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋  

  34. Development a novel regenerative treatment for perinatal brain injury with Muse cells Invited International conference

    Yoshiaki Sato

    The 20th Annual Meeting of Infantile Seizure Society 

     More details

    Event date: 2019.5 - 2019.6

    Language:English   Presentation type:Oral presentation (invited, special)  

  35. Development of a novel treatment for perinatal brain injuriesby Multilineage-differentiating stress-enduring cells International conference

    Yoshiaki Sato, Toshihiko Suzuki, Yuma Kitase, Kazuto Ueda, Atsuto Onoda, Ryosuke Miura, Shoji Go, Shinobu Shimizu, Masahiro Tsuji, Masahiro Hayakawa

    IPOKRaTES Japan 2019 conference 

     More details

    Event date: 2019.5

    Language:English   Presentation type:Poster presentation  

  36. 医工連携による新生児医療の発展~脳障害への幹細胞療法の開発を中心に~ Invited

    佐藤義朗

    第2回NLSセミナー・GTRセミナー  2019.3.13 

     More details

    Event date: 2019.3

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:名古屋  

  37. 周産期疾患に対する幹細胞療法~周産期脳障害と慢性肺疾患を中心に~ Invited

    佐藤義朗

    第8回東京都区南部周産期ネットワークグループ研修会  2019.3.1 

     More details

    Event date: 2019.3

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:東京  

  38. 新生児慢性肺疾患と肺高血圧症に対する幹細胞療法 Invited

    佐藤義朗

    シナジスインターネットライブセミナー  2019.2.20 

     More details

    Event date: 2019.2

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:名古屋  

  39. 新生児肺高血圧症に対する幹細胞療法 Invited

    佐藤義朗

    第63回日本新生児成育医学会・学術集会 

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:東京  

  40. 周産期低酸素性虚血性脳症に対する幹細胞療法/再生医療~臨床応用に向けて~ Invited

    佐藤義朗

    平成30年度 西三河周産期医療ネットワーク協議会  2018.11.15 

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:安城  

  41. 幹細胞を用いた新生児慢性肺疾患に対する新規治療法の開発 Invited

    佐藤義朗

    第31回 日本新生児慢性肺疾患研究会  2018.10.20 

     More details

    Event date: 2018.10

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:埼玉  

  42. 幹細胞を用いた新生児慢性肺疾患に対する新規治療法の開発 Invited

    佐藤義朗

    第11回新生児科指導医教育セミナー  2018.8.18 

     More details

    Event date: 2018.8

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:仙台  

  43. 周産期脳障害に対する臍帯血幹細胞療法 Invited

    佐藤義朗

    第6回臍帯血による再生医療研究会  2018.7.22 

     More details

    Event date: 2018.7

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋  

  44. Development of a novel treatment for perinatal brain injuries by Multilineage-differentiating stress-enduring cells International conference

    Yoshiaki Sato, Toshihiko Suzuki, Yuma Kitase, Shinobu Shimizu, Masahiro Tsuji, Masahiro Hayakawa

    11th Hershey Conference on Developmental Brain Injury 

     More details

    Event date: 2018.6

    Language:English   Presentation type:Poster presentation  

    Venue:Pacific Grove, USA  

  45. 新生児慢性肺疾患に伴う肺高血圧症に対する幹細胞療法 Invited

    佐藤義朗

    第16回日本周産期循環管理研究会 

     More details

    Event date: 2018.5

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  46. Development of a novel treatment for neonatal bronchopulmonary dysplasia by multilineage-differentiating stress-enduring cells International conference

    Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Shoji Go, Kazuto Ueda, Haruka Mimatsu, Yuma Kitase, Taichi Kato, Masahiro Hayakawa

    Pediatric Academic Societies (PAS) Annual Meeting 

     More details

    Event date: 2018.5

    Language:English   Presentation type:Poster presentation  

    Venue:Toronto, Canada  

  47. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    第121回日本小児科学会学術集会  2018.4.20 

     More details

    Event date: 2018.4

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:福岡  

  48. 周産期脳障害に対する幹細胞療法~一般医療としての細胞療法を目指して~ Invited

    佐藤義朗

    第6回脳性麻痺予防研究会  2018.3.2 

     More details

    Event date: 2018.3

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:倉敷  

  49. 周産期脳障害~病態から幹細胞療法まで~ Invited

    佐藤義朗

    平成29年度周産期医療従事者研修会  2017.12.16 

     More details

    Event date: 2017.12

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:江南  

  50. Intravenous injection with dedifferentiated fat cells ameliorated neonatal hypoxic ischemic brain injury, possibly via paracrine effects International conference

    Yoshiaki Sato , Alkisti Mikrogeorgiou, Taiki Kondo, Tetsuo Hattori, Yuichiro Sugiyama, Keiko Nakanishi, Masahiro Tsuji, Tomohiko Kazama, Koichiro Kano, Taro Matsumoto, Masahiro Hayakawa

    International Society for Stem Cell Research 2017 Annual Meeting  

     More details

    Event date: 2017.7

    Language:English   Presentation type:Poster presentation  

    Venue:Boston  

  51. 周産期低酸素性虚血性脳症に対する脱分化脂肪細胞を用いた新規治療法の開発 Invited

    佐藤義朗

    第16回日本再医療学会総会 

     More details

    Event date: 2017.3

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:仙台  

  52. 周産期疾患に対するMuse細胞を用いた新規治療法の開発 Invited

    佐藤義朗

    第16回日本再医療学会総会 

     More details

    Event date: 2017.3

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:仙台  

  53. 幹細胞療法にかける思い~私が基礎研究を始めたわけとその後の道のり~ Invited

    佐藤義朗

    289回長野県周産期カンファレンス  2017.3.1 

     More details

    Event date: 2017.3

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:松本  

  54. 幹細胞療法にかける思い~私が基礎研究を始めたわけとその後の道のり~ Invited

    佐藤義朗

    第117回東京新生児研究会  2017.1.10 

     More details

    Event date: 2017.1

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:東京  

  55. 大学院進学;‘臨床の充実感’を超えてめざす意味 Invited

    佐藤義朗

    日本成育医学会・学術集会 

     More details

    Event date: 2016.12

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:大阪  

  56. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    日本蘇生学会第35回大会 

     More details

    Event date: 2016.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:久留米  

  57. Administration of bone marrow mononuclear cells decreases hypoxic-ischemic brain injury in neonatal rats International conference

    Yoshiaki Sato, Taiki Kondo, Tetsuo Hattori, Alkisti Mikrogeorgiou, Yuichiro Sugiyama, Masahiro Tsuji, Keiko Nakanishi, Masahiro Hayakawa

    10th Hershey Conference on Developmental Brain Injury 

     More details

    Event date: 2016.6

    Language:English   Presentation type:Poster presentation  

    Venue:Paris  

  58. 現場での壁を打破したい~新しい治療への夢をあきらめない~ Invited

    佐藤義朗

    第14回周産期循環研究会 

     More details

    Event date: 2016.5

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:福島  

  59. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    第55回岐阜県周産期懇話会  2016.4.9 

     More details

    Event date: 2016.4

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:大垣  

  60. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    2015年度静岡県周産期研究会  2015.10.3 

     More details

    Event date: 2015.10

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:静岡  

  61. 新生児低酸素性虚血性脳症に対する臍帯血幹細胞による治療 Invited

    佐藤義朗

    平成27年度第2回大阪府医師会「周産期医療研修会」  2015.9.26 

     More details

    Event date: 2015.9

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:大阪  

  62. 超音波による下大静脈径と中心静脈圧との相関 Invited

    佐藤義朗、川滝元良、豊島勝昭、加藤太一、猪谷泰史、早川昌弘

    第13回日本周産期循環管理研究会 

     More details

    Event date: 2015.6

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:岐阜  

  63. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    第2 回 新生児科指導医教育セミナー  2015.5.23 

     More details

    Event date: 2015.5

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:仙台  

  64. 臨床現場での壁に立ち向かう ~再生医療/細胞治療にかける思い~ Invited

    佐藤義朗

    第118回日本小児科学会学術集会 

     More details

    Event date: 2015.4

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:大阪  

  65. 「HIEのこれからの治療」幹細胞療法の基礎研究 Invited

    佐藤義朗

    第59回日本未熟児新生児学会 

     More details

    Event date: 2014.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:愛媛  

  66. 低血糖を呈する遅発性進行性周産期脳障害 Invited

    佐藤義朗

    第29回日本母乳哺育学会・学術集会 

     More details

    Event date: 2014.10

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:横浜  

  67. ステロイドホルモン投与の未熟脳への影響 ~動物モデルから~ Invited

    佐藤義朗、中村祐子、早川昌弘

    第50回日本周産期・新生児医学会学術集会 

     More details

    Event date: 2014.7

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:浦和  

  68. Administration of umbilical cord blood cells decreases hypoxic–ischemic brain injury in neonatal rats International conference

    Sato Y, Hattori T, Kondo T, Ichinohashi Y, Sugiyama Y, Tsuji M, Ikeda T, Nakanishi K, Blomgren K, Hayakawa M

    9th Hershey Conference on Developmental Brain Injury  

     More details

    Event date: 2014.6

    Language:English   Presentation type:Poster presentation  

    Venue:セントマイケルズ  

  69. 周産期脳障害に対する幹細胞療法 Invited

    佐藤義朗

    第117回日本小児科学会学術集会 

     More details

    Event date: 2014.4

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋  

  70. 新生児低酸素性虚血性脳症に対する幹細胞療法 Invited

    佐藤義朗

    第39回日本小児神経学会東海地方会 

     More details

    Event date: 2013.7

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋  

  71. Stem cell therapies for perinatal brain injuries Invited International conference

    Yoshiaki Sato

    XI World Congress of Perinatal Medicine 

     More details

    Event date: 2013.6

    Language:English   Presentation type:Oral presentation (invited, special)  

    Venue:モスクワ  

  72. 周産期低酸素性虚血性脳症に対する幹細胞療法 Invited

    佐藤義朗

    12th Conference for BioSignal and Medicine  

     More details

    Event date: 2012.8 - 2012.9

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:伊勢志摩  

  73. Irradiation in developing brain Invited International conference

    Yoshiaki Sato

    The 2nd Annual Meeting of International Society of Radiation Neurobiology 

     More details

    Event date: 2011.12

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  74. 超早産児における中枢神経受傷機序の解明~経時的脳波を用いた検討~ Invited

    佐藤義朗、伊藤美春、早川昌弘、竹本康二、久保田哲夫、近藤大貴、伊東真隆、松沢麻衣子、林誠司、加藤徹、大城誠

    第47回日本周産期・新生児医学会 

     More details

    Event date: 2011.7

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:札幌  

  75. 未熟児網膜症に対する光凝固術施行時の鎮痛・鎮静 Invited

    佐藤義朗, 大城誠, 竹本康二, 細野治樹, 齊藤明子, 近藤大貴, 会津研二, 松沢麻衣子, 寺崎浩子, 早川昌弘

    第29回周産期学シンポジウム 

     More details

    Event date: 2011.1

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:佐賀  

  76. 中枢神経疾患に対する幹細胞療法 ~周産期脳障害の救世主となりうるか~ Invited

    佐藤義朗

    第52回日本小児神経学会総会  2010.5.20 

     More details

    Event date: 2010.5

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:福岡  

  77. The fate of neural progenitor cells grafted into the brains of irradiated juvenile mice International conference

    Yoshiaki Sato, Noriko Shinjyo, Marie Nilsson, Niklas Karlsson, Machiko Sato, Kazuhiro Oosato, Changlian Zhu, Milos Pekny, Marcela Pekna, Klas Blomgren

    The 38th annual meeting of society for neuroscience 

     More details

    Event date: 2008.11

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Washington DC, USA  

  78. Replacement of neural progenitor cells by transplantation into the hippocampus of irradiated juvenile mice International conference

    Yoshiaki Sato, Noriko Shinjyo, Marie Nilsson, Niklas Karlsson, Machiko Sato, Kazuhiro Oosato, Changlian Zhu, Milos Pekny, Marcela Pekna, Klas Blomgren

    NBCNS Network for Neuroblastoma and CNS tumor research in Sweden, Second Research meeting 

     More details

    Event date: 2008.9

    Language:English   Presentation type:Poster presentation  

    Venue:Solbacka, Sweden.  

  79. Reduction of cerebral degeneration in neonatal hypoxic-ischemic rats by intracerebroventricular injection of neural stem/progenitor cells together with chondroitinase ABC International conference

    Yoshiaki Sato, Keiko Nakanishi, Masahiro Hayakawa, Akiko Saito, Hiroko Kakizawa, Michiru Ida, Yoshihito Tokita, Fumiko Matsui, Sachiko Aono, Seiji Kojima and Atsuhiko Oohira

    The 2nd Congress of Asian Society for Pediatric Research. 

     More details

    Event date: 2006.12

    Language:English   Presentation type:Oral presentation (general)  

  80. A highly sulfated chondroitin sulfate preparation, CS-E, prevents excitatory amino acid-induced neuronal cell death. International conference

    Yoshiaki Sato, Keiko Nakanishi, Masahiro Hayakawa, Akiko Saito, Hiroko Kakizawa, Michiru Ida, Yoshihito Tokita, Fumiko Matsui, Sachiko Aono, Seiji Kojima and Atsuhiko Oohira

    The 36th annual meeting of society for neuroscience  

     More details

    Event date: 2006.10

    Language:English   Presentation type:Poster presentation  

    Venue:Atlanta  

  81. Clinical manifestations of parasagittal cerebral injury International conference

    Yoshiaki Sato, Masahiro Hayakawa, Akihisa Okumura, Toru Kato, Motomasa Suzuki, Fumio Hayakawa, Tetsuo Kubota, Koichi Maruyama, Masayuki Hasegawa, Makoto Oshiro, Osamu Kito

    The 1st Congress of Asian Society for Pediatric Research 

     More details

    Event date: 2005.11

    Language:English   Presentation type:Poster presentation  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 9

  1. ゼラチン繊維基材を用いた脂肪幹細胞による横隔膜再生

    2021.4 - 2022.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズA 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3500000 ( Direct Cost: \3500000 )

  2. Muse細胞を用いた周産期脳障害の新規治療法開発 探索的臨床試験(医師主導治験)

    2020.8 - 2022.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズC 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\123632002 ( Direct Cost: \95101540 、 Indirect Cost:\28530462 )

  3. 新生児の肺障害を修復する多能性幹細胞(Muse細胞)を用いた再生治療の開発

    2020.6 - 2023.3

    国立研究開発法人日本医療研究開発機構  再生医療実現拠点ネットワークプログラム 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\117000000 ( Direct Cost: \90000000 、 Indirect Cost:\27000000 )

  4. 新生児慢性肺疾患の治療薬開発

    2020.4 - 2021.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズA 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\2133942 ( Direct Cost: \2133942 )

  5. 脱脂肪幹細胞を用いた新生児壊死性腸炎に対する新規治療法の開発

    2018.11 - 2019.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズA 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\2945000 ( Direct Cost: \2945000 )

  6. 幹細胞を用いた新生児壊死性腸炎に対する新規治療法の開発

    2018.4 - 2019.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズA 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4000000 ( Direct Cost: \4000000 )

  7. Muse細胞を用いた周産期脳障害の新規治療法開発

    2017.4 - 2019.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズB 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\11389972 ( Direct Cost: \87615170 、 Indirect Cost:\2628455 )

  8. 幹細胞を用いた胎児発育不全による脳障害に対する新規治療法の開発

    2017.4 - 2018.3

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト橋渡し研究戦略的推進プログラム シーズA 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4250000 ( Direct Cost: \4250000 )

  9. Development a novel regenerative treatment for perinatal brain injury with Muse cells

    2016.4 - 2017.3

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\102739000 ( Direct Cost: \79030000 、 Indirect Cost:\23709000 )

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 15

  1. 低出生体重児の神経発達障害の発症機序解明と幹細胞及び母乳中成分を用いた予防法開発

    2021.4 - 2026.3

    科学研究費補助金  国際共同研究強化B

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \1500000 )

  2. 小脳障害に着目した早産児の神経学的障害の病態解明と幹細胞療法の治療機序解明

    Grant number:21K07794  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(C)

    佐藤 義朗, 飛田 秀樹, 湯川 博, 小野田 淳人

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    新生児医療の進歩により早産児の死亡率は大きく改善したが、神経学的障害を残す児の数は減っていない。これまで神経学的障害の原因として大脳病変が言われており広く研究されてきたが、小脳病変は着目されてこなかった。小脳病変の病理病態の解明が、早産児に生じる神経学障害を改善する新規治療法の開発に繋がると考え、本研究では、“早産児に伴う神経学的障害の克服”に対し、小脳障害に焦点を当て研究を行う。

  3. A Study of Neonatal Respiration and Heartbeat Measuring Method Using Doppler Sensor

    Grant number:21K12717  2021.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \800000 )

  4. 肺高血圧症の閉塞性病変における平滑筋細胞形質変換のプロテオームによる網羅的解析

    Grant number:20K08155  2020.4 - 2023.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    加藤 太一, 佐藤 義朗, 山本 英範

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \300000 )

    肺高血圧症は、肺動脈が進行性に狭窄、閉塞する難治性疾患であり、重篤な場合、生命予後が不良な疾患です。この研究は実験的に作成した肺高血圧モデルにおいて、血管が閉塞している部分と閉塞していない部分のそれぞれから蛋白質を抽出し、プロテオーム解析という手法で、両者で異なる蛋白質すなわち閉塞に関連する蛋白質を同定し、その機能を検証することで、病気のメカニズムを解明することを目的としています。
    本研究では、ラット肺高血圧モデルにおいて、肺高血圧症の閉塞性病変における平滑筋細胞の形質変換に関与する蛋白を、レーザーマイクロダイセクションにより閉塞性病変の組織を選択的に取得して、プロテオーム解析による網羅的探索を行うことで同定し、機能を検証することを目的としている。閉塞性病変を起こすラットSugen-低酸素モデルはVEGF受容体遮断薬のSugen5416をラットに皮下注後、0.5気圧下で3週間飼育したのちに通常気圧化で飼育することで徐々に閉塞性病変が出現する。研究代表者らの既報では通常気圧下5週間時点で約25%の肺血管で閉塞性病変が出現するため、当初は低酸素3週間の後、通常気圧下5週時点での閉塞性病変と非閉塞病変の組織をレーザーマイクロダイセクションにて得る予定としていた。しかしながら、今回使用したラットでは通常気圧下5週時点では閉塞性病変の比率が既報よりも少なく、改めて時系列で病変の再検討を行った。7週齢の雄SDラットに対し、Sugen5416皮下注後3週間の低酸素と5週間(8週モデル)または10週間(13週モデル)の通常気圧下で飼育したラットを作成した。13週モデルは8週モデルに比して右室圧はやや上昇し、右室/左室+心室中隔の重量比は有意に増加していた。また、8週モデルでは閉塞性病変も認めるがわずかであり、中膜肥厚のみの変化が目立ったのに対し、13週モデルでは閉塞性病変が増えていた。以上から当初の8週モデルの同一個体内での閉塞病変と非閉塞病変の比較よりも、8週モデルと13週モデル間で病変を比較する方がよいと考えられた。現在各群6匹ずつのモデルラットを作成、血行動態評価、病理評価を行い、レーザーマイクロダイセクションにて病変部位の組織を取得中である。
    本研究では、当初既報を元に8週モデルの同一個体内での閉塞病変と非閉塞病変の比較を行う予定であった。しかしながら、個体差によるものかSugen5416のロット差によるものかは不明だが、想定よりも8週モデルでの閉塞性病変が目立たなかった。そのため、モデル間の比較を最適化するための時系列を変えた病理評価が必要となり、予定より時間を要した。検討の結果、8週モデルと13週モデル間で閉塞病変と非閉塞病変を比較する形がその後のレーザーマイクロダイセクションおよびプロテオーム解析に有用と判断した。
    時系列評価によって適切な比較対象が確定したことから、現在はレーザーマイクロダイセクションにて血管病変の取得を行っている。なお、肺血管の閉塞病変は50-200μm径のものが中心であり、プロテオーム解析に必要な蛋白量の検討も必要と考えられた。そのため、実質臓器(ラット肝臓)を用いて、同様のサイズのものについて何か所のダイセクションにより必要蛋白量を得られるかを検討し、その結果を踏まえて肺血管のレーザーマイクロダイセクションを行っている。8週モデルと13週モデルで各群6匹ずつを得、プールされたサンプルではなく、個別のサンプルとして2群間の発現蛋白の比較をプロテオーム解析にて行う予定であり、現在のところ6割のサンプル取得が終了した。

  5. "再生”を用いた新生児/小児肺高血圧症に対する新規治療法の開発

    Grant number:19K08250  2019.4 - 2022.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    齊藤 明子

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \150000 )

    新生児/小児の肺高血圧症(PAH)は、予後不良で難治の疾患である。
    PAHに伴う心拍出量低下や右心不全は患者のQOLを著しく低下させ、死亡率は依然として高い。
    現状では複数の薬剤を併用投与するが、その効果には限界があり、PAHの患者に見られる広範な微小血管床の喪失には無効である。
    PAHの新たな治療方策のひとつとして、再生/細胞療法が挙げられる。
    本研究では、A細胞がPAHにおいて有効であることを示し、新規治療につなげるための基礎研究を行う。

  6. Elucidation of severe mechanism and development of novel therapy against chronic lung disease in SGA infants caused by pregnancy induced hypertension

    Grant number:19K08341  2019.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \150000 )

  7. Development of a novel two-step cell therapy for perinatal hypoxic ischemic encephalopathy

    Grant number:17K10175  2017.4 - 2020.3

    Sato Yoshiaki

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    The purpose of this study was to develop a novel therapy for perinatal HIE using allogenic and autologous UMSCs.
    In the present study, we established a method to obtain homogeneous UCMSCs from rat umbilical cords. The intravenously administered UCMSCs were engrafted in the brain, lungs, and liver.
    However, immunohistological evaluation after acute phase treatment did not show the treatment effect of UCMSC. In the behavioral evaluation after chronic treatment, some behavioral abnormalities were observed in HIE model rats, but no treatment effect was confirmed by UCMSC administration.

  8. The development of cell therapies for complications in several organs in infants with CLD

    Grant number:16K15534  2016.4 - 2019.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research  Grant-in-Aid for Challenging Exploratory Research

    Hayakawa Masahiro

      More details

    Authorship:Coinvestigator(s) 

    Direct Cost: \150000 )

    Neonatal chronic lung disease is a risk factor for not only respiratory disorder but also psychomotor developmental delay. And it is well known that that it may affect various organs other than respiratory organs. In this study, we investigated the effects of multiple organs to administer 7ND-MSC and Multilineage-differentiating stress enduring cells (Muse cells). Intravenous administration of 7ND-MSC and Muse cells suppresses systemic inflammation and airway inflammation more strongly than normal mesenchymal stem cells, and is effective in treating alveolar developmental disorders in lung tissue and pulmonary hypertensive changes in the heart.

  9. Development of a novel treatment for neonatal chronic lung disease by stem cells

    Grant number:16K19683  2016.4 - 2019.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    Saito Akiko, Sato Yoshiaki, Suzuki Toshihiko

      More details

    Direct Cost: \150000 )

    Neonatal chronic lung disease (CLD) is still an important complication in very low birth weight infants (VLBW). Stem cell therapy using various cell sources has been recently identified as a novel therapy for CLD. Multilineage-differentiating stress-enduring (Muse) cells are a novel type of endogenous stem cells that are able to self-renew, display pluripotency. The purpose of this study was to evaluate the treatment effect of Muse cells on CLD using a rat model.
    In this study, we have shown that (1) intravenously injected Muse cells migrated into injured lung in CLD model rats, and the number of them was higher than that of non-Muse Mesenchymal Stem Cells (MSCs). (2) Muse cells injected intravenously ameliorated impaired alveolar growth induced by hyperoxia in the rat model, and the beneficial effect was much more evident than that done by non-Muse MSCs. (3) Muse cells, but not non-Muse cells, ameliorated impaired pulmonary hypertension in the CLD model.

  10. Development of novel therapy for chronic lung disease associated pulmonary arterial hypertension via proliferation of pulmonary alveoli.

    Grant number:15K09687  2015.4 - 2018.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KATO TAICHI

      More details

    Authorship:Collaborating Investigator(s) (not designated on Grant-in-Aid) 

    In this study, we studied whether EGF promoted the proliferation of pulmonary alveoli and improved pulmonary hypertension using hyperoxia induced chronic lung disease rat neonate model. The time course study on the duration of hyperoxia revealed that compared to control rats, systolic right ventricular pressure (RVP) and the percentage of muscularized pulmonary vessels increased significantly in the rats after 14 days of hyperoxia challenge. Daily administration of EGF slightly decreased RVP and the percentage of muscularized pulmonary vessels and slightly improved the structure of pulmonary alveoli. Furthermore, hyperoxia decreased the expression of BMPR2, FGFR1 and MMP14 in the lung, which was not restored by EGF. These results showed chronic hyperoxia for 14 days caused chronic lung disease associated pulmonary hypertension in rat neonates. EGF administration showed only slight improvement of pulmonary hypertension and the structure of pulmonary alveoli in this model.

  11. Stem cell therapy for brain injuries of infants with fetal growth restriction

    Grant number:26293252  2014.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    Hayakawa Masahiro

      More details

    Direct Cost: \300000 )

    Fetal growth retardation is the cause of small-for-gestational age (SGA) and is a high-risk group of neurological post-injury. Various therapeutic interventions have been done to prevent post-neurological impairment, but none of them have been effective. In this study, SGA rats were inferior in early behavioral evaluation of neonates, and immune-histological analysis showed that nerve cells decreased. Intravenous administration of umbilical cord blood after birth improved behavior early in the neonatal period and also significantly increased neuronal cells immunologically. This suggested the possibility of novel therapy for neurological development of children with SGA.

  12. Development of a novel therapy for perinatal brain injury with dedifferentiated fat cells

    Grant number:26461630  2014.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Sato Yoshiaki, MATSUMOTO TARO, TSUHI MASAHIRO

      More details

    Grant amount:\4940000 ( Direct Cost: \3800000 、 Indirect Cost:\1140000 )

    In the present study, we aimed to determine whether the outcome of HIE can be improved by DFAT cell treatment. 24 h after HI insult, DFAT cells were injected at 10^5 cells/pup into the right external jugular vein. The number of cells that stained positive for active caspase-3, ED-1, and 4-HNE decreased in the DFAT-treated group. The HI insult led to a motor deficit according to the rotarod treadmill and cylinder test, where it significantly affected the vehicle group, whereas no difference was confirmed between the DFAT and sham groups. According to in vitro experiments, the cell death rates in the DFAT-CM-treated cells were significantly lower than those in the controls. In the DFAT-CM, several neurotrophic factors, IGF-1、NGF、NT3 were detected, and these factors were increased in the ipsilateral brain after injection of DFAT. Our results indicate that intravenous injection with DFAT cells is effective for ameliorating HI brain injury, possibly via paracrine effects.

  13. Transplantation of rat umbilical cord blood cells for neonatal hypoxic-ischemic brain injury.

    Grant number:25461659  2013.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    NAKANISHI KEIKO, SATO YOSHIAKI, ITO MIHARU, HIGASHI YUJIRO, MIZUTANI YUKA, HIRAKAWA AKIHIRO

      More details

    Mononuclear cells isolated from rat umbilical cord blood were expanded (stem cell enriched-umbilical cord blood cells; SCE-UCBCs) and they were administered intraperitoneally to neonatal hypoxic-ischemic encephalopathy (HIE) model of rats. Administration of SCE-UCBCs increased the residual brain volume and decreased the accumulation of activated microglia to lesion site. These results indicate that UCBCs could ameliorate HI injury, possibly through an endogenous response.

  14. 周産期脳障害に対する骨髄幹細胞を用いた新規治療開発

    2011.4 - 2014.3

    科学研究費補助金  若手研究(B)

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

  15. 臍帯血幹細胞を用いた周産期脳障害の治療開発

    2009.4 - 2011.3

    科学研究費補助金  研究活動スタート支援

    佐藤義朗

      More details

    Grant amount:\2535000 ( Direct Cost: \1950000 、 Indirect Cost:\585000 )

▼display all

Industrial property rights 9

  1. 低酸素性虚血性脳症の予防又は治療剤及びその利用

    佐藤義朗 齊藤明子

     More details

    Applicant:名古屋大学

    Application no:2014-22411  Date applied:2014.2

    Country of applicant:Domestic  

  2. 神経細胞の細胞死抑制剤等

    大平敦彦、佐藤義朗、中西圭子、前田 浩

     More details

    Applicant:愛知県と生化学工業株式会社

    Application no:2006-13981  Date applied:2006.5

    Announcement no:2007-30861 

    Country of applicant:Domestic  

  3. 脳損傷抑制剤

    大平敦彦、佐藤義朗、中西圭子、前田 浩

     More details

    Applicant:愛知県と生化学工業株式会社

    Application no:2006-139843  Date applied:2006.5

    Patent/Registration no:5279491  Date registered:2013.5 

    Country of applicant:Domestic  

  4. 脳損傷改善剤

    大平敦彦、佐藤義朗、中西圭子、前田 浩

     More details

    Applicant:愛知県と生化学工業株式会社

    Application no:PCT/JP2007/060388  Date applied:2007.5

    Country of applicant:Foreign country  

  5. 呼吸補助治療具

    伊藤 美春, 佐藤 義朗, 早川 昌弘, 高▼成 啓介, 亀井 讓

     More details

    Applicant:国立大学法人名古屋大学

    Application no:特願2018-085877  Date applied:2018.4

    Announcement no:特開2019-187947  Date announced:2019.10

    J-GLOBAL

  6. 多能性幹細胞による慢性肺疾患の改善及び治療

    佐藤 義朗, 鈴木 俊彦, 清水 忍, 水野 正明, 早川 昌弘, 出澤 真理

     More details

    Applicant:国立大学法人名古屋大学, 株式会社生命科学インスティテュート, 国立大学法人東北大学

    Application no:JP2017028323  Date applied:2017.8

    Announcement no:WO2018-025973  Date announced:2018.2

    J-GLOBAL

  7. 多能性幹細胞による周産期脳障害の改善及び治療

    佐藤 義朗, 鈴木 俊彦, 清水 忍, 水野 正明, 早川 昌弘, 出澤 真理

     More details

    Applicant:国立大学法人名古屋大学, 株式会社生命科学インスティテュート

    Application no:JP2017018416  Date applied:2017.5

    Announcement no:WO2017-199976  Date announced:2017.11

    J-GLOBAL

  8. 精子活性化方法及びその用途

    山本 徳則, 鈴木 哲, 松川 宜久, 舟橋 康人, 佐藤 義朗, 後藤 百万, 村瀬 哲磨

     More details

    Applicant:国立大学法人名古屋大学, 国立大学法人岐阜大学

    Application no:特願2013-222630  Date applied:2013.10

    Announcement no:特開2015-082987  Date announced:2015.4

    Patent/Registration no:特許第6241819号  Date issued:2017.11

    J-GLOBAL

  9. 精子活性化方法及びその用途

    山本 徳則, 鈴木 哲, 松川 宣久, 舟橋 康人, 佐藤 義朗, 後藤 百万, 村瀬 哲磨

     More details

    Application no:2013-222630  Date applied:2011.10

    Country of applicant:Domestic  

▼display all